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ABSTRACT 
Breast cancer is a major cause of cancer-related death among women 
throughout the world. Treatment of breast cancer often fails due to the development of 
resistance to both chemo- and radiotherapy. 
The aim of this study was to analyze and compare the response to radiation of 
MCF-7 breast adenocarcinoma cells and MCF-7 cells that are resistant to doxorubicin 
(MCF-7/DOX). The results presented in this thesis show that drug-resistant MCF-
7/DOX cells survive high doses of radiation exposure better than MCF-7 cells. 
Moreover, the chemo- and radioresistance of MCF-7/DOX cells share common 
molecular mechanisms and loss of sensitivity to radiation in chemo-resistant cells may 
be explained by alterations in their DNA methylation profile. 
The results of experiments presented in this thesis may, therefore, serve as a 
first step for future analysis of tumour resistance to radio- and chemotherapy and for 
the development of novel epigenetic strategies for reversal of breast cancer resistance 
to cytotoxic treatment regimens. 
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CHAPTER 1: GENERAL INTRODUCTION 
BREAST CANCER AND BREAST CANCER TREATMENT OPTIONS 
Breast cancer develops as an uncontrolled growth of breast cells that often 
form malignant tumors. Breast cancer is one of the major clinical challenges 
throughout the world (Russo, et al., 2000). It has become the second leading cause of 
cancer-related deaths among North American women and the leading cause of death 
among women aged 35 to 55 years (Schairer et al., 2004; Widschwendter and Jones, 
2002). According to Canadian Cancer Statistics (2009) breast cancer accounts for up 
to 22,700 new cases among Canadian women in 2009 with total deaths of 5,400 
(www.cancer.ca/statistics). The histological origin of breast cancer can be either 
lobular that begins in the milk producing glands or ductular when a tumor originates 
in ducts that carry milk from the glands to the nipple (www.breastcancer.org).  
Numerous clinical studies identified several main breast cancer risk factors 
(Pike et all., 1993). About 5 – 10 % of breast cancers are hereditary, caused by 
mutations in breast cancer susceptibility genes BRCA1 and BRCA2 which normally 
prevent uncontrolled cell growth. Other genes which, when mutated, can be associated 
with breast cancer are: the DNA repair gene ATM, the tumour suppressor gene p53, 
the cell growth regulator PTEN, and the human epidermal growth factor HER2 (Russo 
et al., 2000). Estrogen (E2) is a well-known hormonal breast carcinogen. Women with 
elevated E2 levels are considered to be a high-risk group for breast cancer 
development (Bernstein and Ross, 1993). Other breast cancer risk factors include age, 
exposure to ionizing radiation, increased alcohol consumption, postmenopausal 
obesity and nulliparity (Russo and Russo, 2004). 
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The main treatment approaches are based on a patient‘s risk level and stage of 
cancer. For the majority of patients, surgery followed by radiation and chemotherapy 
is a standard treatment procedure (Guarneri and Conte, 2004; Veronesi, 1990). A 
breast cancer treatment plan is a doctor‘s/patient‘s choice made from the whole menu 
of treatment options available now.  
Surgery is usually the first line of attack against breast cancer (Arriagada et al., 
1996). Systemic therapy is a form of treatment that affects the whole body through the 
bloodstream. Hormonal therapy and chemotherapy are commonly used types of 
systemic therapy (National Cancer Institute: www.cancer.gov). Hormonal or anti-
estrogen therapy is used against hormone-receptor-positive breast cancer and is based 
on blocking the action of estrogen (www.breastcancer.org), while chemotherapy is 
based on the usage of drugs to kill cancer cells 
(www.breastcancer.org/treatment/chemotherapy). Radiation therapy, or radiotherapy, 
is a highly targeted way of cell killing using a high-energy beam of ionizing radiation 
to damage DNA in cancer cells (www.breastcancer.org/treatment/radiation). 
  
CHEMOTHERAPY AND CHEMORESISTANCE 
TYPES OF CHEMOTHERAPY 
Chemotherapy is based on the usage of one drug or a combination of drugs to 
kill cancer cells. In contrast to surgery or radiotherapy, it does not have a local effect 
but targets different types of cells and organs as a chemodrug is transported 
throughout the body by blood. Depending on treatment goals, there are at least three 
types of chemotherapy treatment: a. neoadjuvant chemotherapy is used to reduce the 
 3 
size of tumour before surgery or radiotherapy (Kuremsky et al., 2009); b. adjuvant 
chemotherapy when drugs are used to remove residual cancer cells remaining in the 
body after other treatments (Winter-Roach et al., 2009); c. combination chemotherapy 
that is used to destroy cancer by itself or in combination with other treatments (Baum 
et al., 2002). 
The most common chemotherapy agents for breast cancer are:  
 alkylating agents that bind to DNA and break links between DNA 
strands (melphalan, cyclophosphamide, cisplatin); 
 anticancer antibiotics that  inhibit topoisomerase which induces DNA 
breaks (doxorubicin, daunomycin, dactinomycin); 
 drugs derived from plants that damage mitotic spindle (taxanes, 
vinblastine); 
 antimetabolites that inhibit enzymes participating in DNA and RNA 
synthesis (methotrexate, 5-azacytosine) (Stavrovskaya, 2000).  
ANTHRACYCLINES AS ANTI-CANCER AGENTS 
Amongst the agents listed above, anthracyclines have the widest spectrum of 
activity in cancers, and only a few cancers (e.g., colon cancer) do not respond to them 
(Weiss, 1992). Doxorubicin was one of the first two anthracyclines with high toxicity 
in mammalian cells in vitro and in vivo (Barranco et al., 1973; Lomovskaya et al., 
1999). 
Doxorubicin hydrochloride is used for treatment of a wide variety of cancers 
such as cancer of the bladder, breast, head and neck, liver, lung, blood (leukemia), 
lymph (lymphoma), ovaries, pancreas, prostate, stomach, testis, thyroid and uterus and 
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mesothelioma, multiple myeloma, neuroblastoma and sarcoma. 
(www.chemocare.com/bio/doxorubicin.asp). Doxorubicin was isolated from the 
bacterium Streptomyces peucetius var. caesius (Lomovskaya et al., 1999). Cells in the 
S phase of the cell cycle are the most sensitive to the cytotoxic action of doxorubicin. 
The cytotoxic activity of doxorubicin is based on the DNA intercalating property of 
this drug. Doxorubicin creates a complex with DNA by intercalating its chromophore 
group in GC-rich sequences, while the groups in the rings form hydrogen bond with 
the base pairs above and below the intercalation site (Manfait et al., 1982). Such 
complexes interfere with polynucleotide synthesis. The main target for doxorubicin is 
the enzyme topoisomerase 2α (Top2A) that is important for unwinding DNA for 
transcription and replicaton. Mechanistically, doxorubicin intercalates DNA and 
inhibits the progression of Top2A. Functionally, it stabilizes the Top2A complex after 
it breaks the DNA chain, thus preventing DNA resealing and thereby blocking 
replication (Fornari et al., 1994; Fortune and Osheroff, 2000; Frederick et al., 1990). 
Inhibition of topoisomerase II by doxorubicin is accompanied by the formation of free 
radical-mediated double-strand breaks in DNA. Cytotoxicity of oxygen free radicals 
formed by doxorubicin action is secondary to lipid peroxidation of cell membrane 
lipids (Fornari et al., 1994). In addition, several studies reported the ability of 
doxorubicin to inhibit the viral, bacterial, and mammalian DNA-dependent DNA 
polymerase and bacterial RNA polymerase (Momparler et al., 1976). 
Doxorubicin and epirubicin (differing chemically from doxorubicin only in the 
spatial orientation of one hydroxyl group) are frequently used in the curative-intent 
adjuvant and palliative treatment of metastatic breast cancer (Dean-Colomb and 
Esteva, 2008; Fornari et al., 1994). Although, doxorubicin is among the most active 
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agents in breast cancer treatment, many women experience a relapse. Furthermore, 
approximately half of women with metastatic breast cancer fail to respond to 
doxorubicin, and the majority of those showing initial benefits subsequently 
demonstrate acquired clinical resistance, as demonstrated by tumor growth despite 
ongoing anthracycline therapy (Dean-Colomb and Esteva, 2008; Fornari et al., 1994). 
Chemoresistance can be broadly defined as protection of cancer cells against 
chemotherapy. 
MULTIPLE DRUG RESISTANCE (MDR) 
General principles of MDR 
Because mechanisms of chemoresistance are multifactorial and tumour cells 
develop many ways to eliminate effects of chemotherapy drugs, resistance often 
develops to a broad spectrum of drugs and cells acquire multiple drug resistance 
(MDR) (Ling, 1997; Stavrovskaya, 1999). MDR is a phenomenon that contributes to 
virtually half of breast cancer deaths and still, unfortunately, remains uncontrollable. 
Therefore, the problem of MDR is actively researched (Gonzalez-Angulo et al., 2007). 
There are two main goals in studying MDR: a) understanding the mechanisms of 
MDR in breast cancer cells; b) reversal of the MDR phenotype to form drug-sensitive 
cells.  
Overall, MDR is a multi-factorial phenomenon involving numerous 
mechanisms (Lehnert, 1996; Shishova and Chekhun, 2000; Szakăcs et al., 2006). At 
present, several major mechanisms are being investigated for their involvement in 
acquired chemotherapeutic drug resistance in cancer cells. These include: decreased 
uptake of water-soluble drugs which require transporters to enter cells (Gottesman, 
2002); various cellular changes such as alterations in cell cycle and signal 
 6 
transduction pathways; increased repair of DNA damage; reduced apoptosis; altered 
drug metabolism that diminishes the capacity of cytotoxic drugs to kill cancer cells 
(Hickman, 1996; Pommier et al., 2004; Stavrovskaya, 2000); increased energy-
dependent efflux of hydrophobic drugs (Gotteman, 2002; Gottesman and Ling, 2006); 
and increased DNA tolerance to DNA- damaging drugs through the inactivation of 
DNA repair pathways (Karran, 2001). 
Efflux pumps and chemoresistance 
A decrease in drug accumulation can result from either a decreased drug influx 
or an increased drug efflux. Obviously, both are connected to changes in the plasma 
membrane. Drug-resistant and drug-sensitive cancer cells often have different lipid 
composition (Simon and Schindler, 1994), but the main difference is the presence of 
energy-dependant pumps which exclude cytotoxic substances from cells. The two 
main ATP-dependant pumps that are currently characterized are a P-glycoprotein 
(Pgp-MDR) and a multidrug resistance-associated protein (MRP) (Kars et al., 2006; 
Ling, 1997). Pgp-MDR1 and MRP belong to the superfamily of ABC (ATP-Binding 
Cassette) transporters which transport different substrates ranging from inorganic ions 
to polysaccharides, proteins and drugs (Higgins, 1995). Both proteins are expressed in 
normal tissues at low levels. Their expression levels are significantly increased in cells 
with acquired chemoresistance (Chekhun et al. 2007; Thottassery et al., 1997). Pgp is 
a large transmembrane glycoprotein encoded by the MDR1 gene. It consists of two 
subunits and includes six hydrophobic transmembrane segments and two ATP-binding 
domains. Substrate binding sites (e.g. anti-cancer drugs) are located in the 
transmembrane domains or under the membrane (Bosh and Croop, 1996). The drug 
molecule binds to a specific site on MDR1 and is transported from the cell after ATP 
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hydrolysis. There are some recent suggestions that this protein may function as a 
flipase which moves substances out of the cell (Higgins et al., 1997).  
The MRP protein is encoded by the MRP1 gene and causes resistance of 
cancer cells to drugs identical to that one mediated by MDR1. The functional activity 
of MRP is different from MDR1 as it requires cellular glutathione for drug effluxing 
(GS-X pump) (Borst et al., 1997; Deeley and Cole, 1997; Morrow and Cowan, 1990). 
Glutathione interacts via its thiol with a chemo drug. A drug and thiol conjugate is 
water-soluble and less toxic. Moreover, it can be excluded from the cell by GS-X 
pumps (Stavrovskaya, 2000). Numerous studies indicate that increased levels of 
glutathione and its isoenzyme GST  are frequently found in chemoresistant cells 
(Tew, 1994). 
DNA repair and chemoresistance 
The cytotoxic effect of many anti-cancer drugs is based on the ability of these 
drugs to cause DNA damage. Therefore, the MDR phenotype can be associated with 
the ability to remove potentially lethal DNA lesions. Several studies indicate an 
increased DNA repair potential in MDR cells. The main DNA repair pathways 
involved in chemoresistance are: nucleotide-excision repair (NER) which removes 
DNA adducts produced by some therapeutic anti-cancer drugs, base excision repair 
(BER) that removes more subtle forms of DNA damage such as oxidized/reduced 
bases, chemically modified bases and small adducts, and the single-strand and double-
strand break repair pathways (Karran, 2001). Paradoxically, inactivation of mismatch 
(MMR) repair is accompanied by tolerance to the cytotoxic effect of some drugs 
(Buermeyer et al., 1999). In MDR cells, potentially lethal DNA lesions are often not 
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excised from DNA but instead become persistent and uncoupled from cell death 
(Karran, 2001). Changes in DNA repair in chemoresistant cells can be explained not 
only by elevated amounts of proteins which repair DNA but also by increased levels 
of some proteins involved in recognizing DNA injury and recruiting repair complexes 
to damaged sites (Chu, 1994).  
Apoptosis and chemoresistance 
A common feature of drug-resistant cancer cells is that they exhibit a profound 
resistance to apoptosis. Examples of numerous alterations that cause resistance to 
apoptosis in advanced cancers are: activation of pro-survival signal transduction 
pathways mediated by Ras, PI3K/Akt, or NF-kB; inactivation of apoptotic pathways 
due to mutation or silencing of p53, pRb, Bax, Bad, Apaf-1, caspase-8 genes or 
overexpression of pro-survival proteins such as Bcl-2, IAP, and FLIP, and others 
(Fesik, 2005). It has recently been found that drug-resistant cancer cells isolated from 
metastatic sites expressed very high levels of a multifunctional protein, tissue 
transglutaminase (TG2), compared to the parental drug-sensitive cell line from which 
they were derived. TG2 is known to associate with integrin proteins and promote 
stable interactions between cells and the extracellular matrix, resulting in increased 
cell survival, cell migration and invasion. TG2 also causes activation of the nuclear 
transcription factor-kB (NF-kB) (Verma and Mehta, 2007). The anti-oncogene PTEN 
can also influence drug resistance. PTEN is a tumor suppressor and a broad spectrum 
phosphatase which negatively regulates the phosphatidylinositol 3‘-kinase (PI3‘K) 
PKB/Akt signalling pathway. It was shown that PTEN-deficient cells demonstrated 
resistance to some cytotoxic agents (Stambolic et al., 1998). 
Doxorubicin resistance 
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As mentioned above, doxorubicin is one of the most widely used drugs for 
treatment of different types of cancer, including breast cancer. But it is also a well 
known fact that cancer cells quickly develop resistance to doxorubicin. Furthermore, 
resistance to the maximum tolerable dose (MTD) of doxorubicin was quickly and 
readily obtained in mammary tumours in mice with conditionally mutated p53 and 
Brca1 tumour suppressor genes (Rottenberg et al., 2007). Tolerance to doxorubicin 
includes various mechanisms, some of which are well studied and described. It is 
known that doxorubicin-resistant cells such as MCF-7 breast adenocarcinoma cells are 
Pgp-MDR1 and MRP1 positive. Such cells express both MDR1 and MRP1 genes 
which code for ABC transporters involved in export of doxorubicin out of the cell 
before it can reach its target (Kars et al., 2006). An interesting fact about doxorubicin 
resistance mediated by Pgp is cross-resistance to taxanes because other biochemical 
doxorubicin resistance mechanisms do not affect taxane sensitivity (Rottenberg et al., 
2007). As an inhibitor of topoisomerase II, doxorubicin stabilizes the DNA-
topoisomerase complex which under normal circumstances is easily disassembled. In 
doxorubicin-resistant cells, the activity and quantities of this enzyme are reduced. 
Mutations in the topoisomerase II gene could also be a cause of drug resistance and 
elevated expression of tissue transglutaminase (TG2) in doxorubicin resistant cells 
was also reported (Verma and Mehta, 2007). Moreover, doxorubicin resistant cells 
have reduced susceptibility to DNA single- and double-strand breaks, and DNA 
damage is more prolonged and might be lethal in sensitive cells, while it is repairable 
in doxorubicin resistant cells (Goldenberg et al., 1986).  
GST is also implicated in resistance of cancer cells to doxorubicin (Batist et 
al., 1986). Elevation of anionic GST has been described in human MCF-7 cells 
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resistant to doxorubicin, and in some cases, GST activity was 50 % higher in drug-
resistant cells compared to sensitive lines (Deffie et al., 1988). All of the above is the 
evidence that resistance to doxorubicin is a multifactorial phenomenon. Such 
multifactorial resistance to doxorubicin may explain cross-resistance of doxorubicin-
resistant cells to other compounds that in some cases are not even structurally related 
such as actimomycin D, daunorubicin, mitoxantrone, colchicines and etoposide 
(Deffie et al., 1988). 
 
RADIATION THERAPY AND RADIORESISTANCE 
Radiation therapy is the use of ionizing radiation to destroy cancer cells; it has 
been practiced in cancer therapy for more than a hundred years (Camphausen and 
Lawrence, 2008). Radiotherapy has become a recognized treatment modality for 
breast cancer patients. It is considered mandatory for patients undergoing conservative 
surgery and is appropriate for women at high risk of recurrence after mastectomy 
(Pierce et al., 2000). 
Radiotherapy works by damaging the DNA of cells (Cuzick, 2005). 
Radiation induces a variety of DNA lesions such as damage to nucleotide bases, 
cross-linking, DNA single- and double-strand breaks (Little, 2000). The limitation of 
radiotherapy is that solid tumour cells often become deficient in oxygen after radiation 
exposure. This means that such tumours can outgrow their blood supply causing 
hypoxia (Harrison et al., 2002). In order for radiation to form DNA-damaging free 
radicals, the presence of oxygen is crucial. Under hypoxic conditions, cancer cells can 
be 2 to 3 times more resistant to radiation. Because oxygen is a strong radiosensitizer, 
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much research has been devoted to the development of blood substitutes that carry 
increased oxygen (Harrison et al., 2002).  
In general, each type of cancer has different radiosensitivity (Nunez et al., 
1996). Breast cancers are ranked as from moderately radiosensitive to radioresistant, 
therefore requiring significantly higher doses of radiation (45-60 Gy) to achieve 
radical cure than many other tumor types. The total dose is devided into 1.8-2 Gy 
fractions per day for several weeks (Tutt and Yarnold, 2006). Undifferentiated breast 
cancer cells generally reproduce faster and have lower capacity to repair sub-lethal 
damage caused by ionizing radiation in comparison to healthy differentiated cells. 
Therefore, fractionation allows normal cells to recover, while tumour cells are less 
efficient in repair between fractions (Pedraza Muriel, 2002). 
There are two types of radiation therapy applied in breast cancer treatment: 
external and internal radiotherapy. External beam radiation is the most common 
radiation given after surgery. In this technique, a special X-ray machine called a 
simulator delivers a beam of high-energy radiation to the area of cancer. Internal 
radiation or brachytherapy is a less common form of radiation treatment after 
lumpectomy. During brachytherapy, small pieces of radioactive material called seeds 
are placed at the tumor area of the breast and the seeds emit radiation into the 
surrounding tissue (www.breastcancer.org/treatment/radiotherapy). 
Radiotherapy can be used as a primary treatment, or it can be combined with 
surgery, chemotherapy or hormone therapy (Koukourakis et al., 1999). In about 70 % 
of breast cancer cases, radiotherapy reduces the risk of relapse (Cuzick, 2005). At 
least half of patients who develop recurrences after surgery and radiotherapy have 
invasive cancer with a high risk of metastasis and death (Boyages et al., 1999). In 
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patients who develop disease recurrence, the actual resistance mechanisms to 
radiotherapy remain unclear but the biology of radioresistance in breast cancer cells 
includes various extra-nuclear and intra-nuclear factors (Jameel et al., 2004). 
Some extra-nuclear factors that cause resistance to radiation: 
1) The insulin-like growth factor-I receptor (IGF-IR) is a tyrosine kinase that 
regulates cell growth, differentiation, transformation and apoptosis (Peretz et al., 
2001). The levels of IGF-IR and its substrate are elevated in ER-positive breast 
tumours and can be linked with increased radioresistance and cancer relapse (Bartucci 
et al., 2001). Some experimental studies on primary breast tumours reported that 
expression of IGF-IR directly influenced radioresistance, and high levels of IGF-IR 
correlated with increased tumour recurrence after radiotherapy (Turner et al., 1997). 
2) The phosphatidylinositol 3-kinase (PI-3K) pathway regulates cell 
progression and cell proliferation and inhibits apoptosis. The main effector of this 
pathway is a serine/threonine protein kinase PKB that initiates S phase and the G2-M 
transition of the cell cycle (Shtivelman, 2003). There are evidences that PI-3K/PKB 
activity contributed to resistance of human breast cancer cells to ionizing radiation. 
Inhibition of the pathway radiosensitized breast cancer cells (Liang et al., 2003).  
3) Epidermal growth factor (EGF) – an extracellular factor which also controls 
cell growth and proliferation. Wollman et al. demonstrated that adding EGF to MCF-7 
cells prior to irradiation caused radioresistance of cells by increasing the fraction of S-
phase cells and glutathione levels (Wollman et al., 1994).  
4) Human epidermal growth factor receptors (HERs) play a role in mammalian 
growth and development (Earp et al., 2003). Some current data show that 
overexpression of EGFRs is widely correlated with resistance to radiotherapy and 
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other forms of adjuvant therapy (Wallman et al., 1994). It has been shown in different 
studies that HER inhibitors affect cellular responses to ionizing radiation inducing 
apoptosis, cell cycle arrest and influencing DNA repair (Sartor et al., 2003). Liang et 
al. showed that using Trastuzumab (Herceptin), an antibody against HER2, sensitized 
breast cells to radiotherapy (Liang et al., 2003).  
5) Vascular endothelial growth factor (VEGF) is an important mediator of 
endothelial cell proliferation, survival and angiogenesis. It is thought that there is a 
link between VEGF overexpression and radioresistance (Gupta et al., 2002). VEGF is 
found to be upregulated under hypoxic conditions, and failure of radiotherapy, as 
mentioned previously, is often associated with tumour hypoxia (Manders et al., 2003; 
Wachsberger et al., 2003).  
Some intracellular factors that affect radioresistance: 
1) p53 mutations are the most common genetic alterations in human breast 
carcinoma which are associated with pure prognosis and chemo/radioresistance due to 
the absence of p53-dependant apoptosis (Marchetti et al., 2003). The mechanism of 
radioresistance development in p53 mutants is believed to be due to loss of control 
over cell cycle, DNA repair and apoptosis. There is a possibility of retention of 
radiation-induced defects in the progeny of irradiated cells (Mazurik and Moroz, 
2001). 
2) BRCA1 and BRCA2 genes are responsible for about 80-90 % of hereditary 
breast cancer (Thull and Vogel). They function as tumour suppressor genes that play 
an important role in homologous recombination DNA repair and NER. Xia et al. 
found upregulation of HR and increased radioresistance when wild type BRCA2 was 
transfected into a BRCA2 defect tumour cell line (Xia et al., 2001), while Abbot et al. 
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showed that human cancer cells containing mutated BRCA1 are hypersensitive to 
ionizing radiation (Abbott et al., 1999). 
3) Telomeres are functional elements of eukaryotic chromosomes responsible 
for maintaining stability of chromosomes, and they play an important role in cellular 
response to DNA damage. McIlrath et al. revealed a seven-fold reduction in telomere 
length in radiosensitive cells in comparison with radioresistant cells, thus concluding 
that telomere length can be used as a marker of radiosensitivity (McIlrath et al., 2001). 
Despite the presence of numerous studies on mechanisms of radioresistance, it 
is still not known how to best distinguish breast cancer patients who would positively 
respond to radiation treatment from those who would develop radioresistance (Jameel 
et al., 2004).  
Radiotherapy is usually combined with anthracycline chemotherapy, and some 
chemoradiation studies confirm local control and survival benefits of such treatment 
(Chakravarthy et al., 2000). Tumour cells of hematopoietic or lymphatic origin 
frequently undergo apoptosis after combined treatment with irradiation and 
doxorubicin (Ling et al., 1993; Skladanowski and Konopa, 1993; Zaleskis et al., 
1994). In contrast, breast cancer is relatively refractory to cell death after either 
irradiation or chemotherapy (Fornari et al., 1996). There is even evidence that cell 
killing and growth inhibition occur only transiently after combined chemo- and 
radiotherapy, and extensive cell-killing tumours even re-grow after irradiation. 
Waldman et al. indicate that cells with intact G1 demonstrate a prolonged cell cycle 
arrest but not apoptosis in response to treatment. This permits re-growth of a sufficient 
number of breast cancer cells which repopulate the breast (Waldman et al., 1997). The 
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absence of apoptosis is associated with chromosomal instability, which can further 
substantiate radioresistance (Morgan et al., 1996).  
Anthracyclines are frequently used as radiosensitizers, but their use often 
results in unacceptable levels of normal tissue toxicity and cardiac toxicity. This 
means that changes in chemo- and radiotherapy administration are needed to reduce 
cancer mortality and treatment side effects and increase the treatment efficacy 
(Cuzick, 2005).  
 
DNA DAMAGE AND REPAIR  
The cytotoxic effect of many anticancer drugs, such as doxorubicin and 
ionizing radiation, relies on the ability of these agents to damage DNA. Interestingly, 
different patients have different levels of sensitivity to drugs and radiotherapy. 
Usually, before treatment decision making, it is important to check radio- and chemo-
sensitivity of breast cancer cells in the laboratory (Girinsky et al., 1992). The main 
indicator of radio- and chemosensitivity of breast cancer cells is the rate of DNA 
damage (usually double-strand breaks) and DNA repair capacity (Kelland et al., 
1988). 
The most common radiation and doxorubicin-induced forms of damage are 
double-strand breaks in DNA. About 40 DNA double-strand breaks are induced in a 
cell for each 1 Gy (Kanaar et al., 1998; Rich et al., 2000). Doxorubicin induces DNA 
breaks by blocking the function of cellular Top2α. There are several features that 
make DSBs difficult to repair. As both strands of DNA are broken, the broken ends 
can dissociate and interact with breaks at other sites that might lead to translocations 
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and deletions. The ends of breaks have sustained damage to bases that need to be 
replaced. In a single-strand break, such bases can be easily replaced using the opposite 
complementary strand as a template, while in DSB such template is unavailable (Tutt 
and Yarnold, 2006). 
The response to radiation and doxorubicin-induced DNA damage includes 
recognizing DSBs and further recruiting a highly regulated signal transduction 
cascade that regulates changes in cell cycle progression and chromatin modifications 
around sites of DNA DSBs. Unrepaired DSB could lead to apoptosis (Rich et al., 
2000). Therefore, recognition of DSB is a sensitive and rapid mechanism. Some data 
suggest that sensing mechanisms may distinguish between DNA damages that could 
be repaired and those which require a wider response, such as cell cycle checkpoint 
activation (Bradbury and Jackson, 2003). Initial sensing molecules are unknown, but 
the main model of DNA damage response suggests recruitment of proteins of the PI3-
kinase-like family to damaged sites and phosphorylation of histones around DSBs. 
The second phase includes signal transducers which recruit repair proteins to the site 
of damage (Tutt and Yarnold, 2006).  
A key component in DSB recognition and DNA repair is histone H2AX which 
becomes rapidly phosphorylated in response to DNA double-strand breaks (Banath et 
al., 2004). H2AX is a variant of histone H2A. Each nucleosome contains 2 to 20 % of 
H2AX depending on the cell type; overall, it is estimated that every fifth nucleosome 
includes an H2AX molecule (Bonner et al., 2008). 
Immediately upon DSB  formation after exposure, PI3K-like kinases, 
including ataxia telangiectasia (ATM), ATM-Rad3-related (ATR) and DNA-
dependant protein kinase (DNA-PK), phosphorylate H2AX and other DNA repair 
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proteins (Bonner et al., 2008). It is believed that phosphorylation occurs within one 
minute after exposure to radiation. The maximum number of phosphorylated H2AX 
(γH2AX) molecules can be reached in 0-30 minutes after exposure and disappear 
slowly over time due to the rejoining of DNA breaks (Sedelnikova and Bonner, 2006). 
The presence of one γH2AX focus represents one physical break; therefore γH2AX 
has become the most popular indicator of DNA damage level. Using an antibody 
against γH2AX reveals the discrete number of DSBs. When double-strand breaks are 
repaired, foci disappear (Pilch et al., 2003). However, some studies indicate that 
γH2AX foci remain elevated even after most DSBs have been rejoined, suggesting 
that γH2AX removal may be dependant on some other mechanisms that follow DNA 
repair (Kinner et al., 2008). Now there are two known mechanisms of γH2AX 
removal: dephosphorylation of γH2AX and removal of γH2AX from the chromatin 
(Bonner et al., 2008). Chowdhury et al. have proved that dephosphorylation is 
performed by protein phosphatase 2A (PP2A) (Chowdhury et al., 2005).  
Overall, the initial detection of DSB involves localization of Nijmegen 
breakage syndrome protein at the site of DSB and two other proteins (MRE11 and 
Rad50) which activate ATM (Kang et al., 2005). ATM activation means dissociation 
of homodimers by phosphorylating each other. Functions of ATM are the following: 
a) chromatin modification by phosphorylation of histone H2AX (described above); b) 
recruitment and regulation of both NHEJ and homologous recombination (HR); c) 
regulation of the cell cycle at G1/S via p53 and MDM2 proteins and at G2/M via 
BRCA1 and CHK1; d) regulation of apoptosis through CHK2 and p53 (Bakkenist and 
Kastan, 2003; Shiloh, 2003; Taylor et al., 1975). The second phase of repair includes 
the work of signal transducers CHK1 and CHK2. CHK1 involves BRCA1 (controls 
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G2/M checkpoint) into the process, confirming that DNA damage is repaired before 
cell division resumes. CHK2 not only regulates G1/S and G2/M checkpoints but also 
helps make a choice between different repair pathways (Tutt and Yarnold, 2006). The 
end of the cascade involves the actual repair proteins. 
The main pathways of DSBs repair are: non-homologous end-joining (NHEJ) 
and Rad51-dependant homologous recombination (HR) (Kanaar et al., 1998). Each of 
them has different consequences on cell survival and genome stability. NHEJ is 
usually active during G0/1 and an early S phase when DSB repair does not depend on 
the presence of a template. NHEJ does not restore the original sequence, and in fact, it 
is highly error- prone, but it does restore the physical integrity of DNA. The actual 
joining of the two ends of the broken DNA requires such proteins as Ku70/Ku80, 
DNA-PKcs, XRCC4 and ligase 4 (Takata et all., 1998; Tutt and Yarnold, 2006; Wang 
et al., 2001).  
Homologous recombination accounts for about 10% of DSBs repair in the 
mammalian genome and occurs during S and G2 phases of the cell cycle (usually in 
less differentiated cells) and requires the presence of a sister chromatid template. A 
homologous sequence of a sister chromatid provides highly accurate repair. This 
process involves an exchange of DNA single strands between homologous 
chromosomes (Jackson, 2002). Lesions having been identified, several proteins begin 
to associate with DNA. These proteins, including RAD52, RAD54 and BRCA2, act as 
mediators and ultimately lead to the presence of RAD51—a protein responsible for 
conducting a homology search (Powell and Kachnic, 2003; Tutt et al, 2001; 
Venkitaraman, 2002). 
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From what we described above, we can briefly conclude that radiosensitive 
cells develop more DSBs per unit dose, and the repair process is slower than in 
resistant cells. It can be directly linked to the confirmation of DNA which varies 
during the cell cycle and establishes the choice of DNA repair pathway. 
 
EPIGENETICS OF DRUG RESISTANCE 
Presently, three hypotheses – genetic, karyotypic and epigenetic – have been 
proposed to explain the mechanisms of acquired cancer drug resistance (Baker and El-
Osta, 2003; Biedler and Spengler, 1994; Duesberg et al., 2007; Fojo, 2007; Glasspool 
et al., 2006; Iwasa et al., 2006; Roberti et al., 2006; Teodoridis et al., 2004). ‗Genetic‘ 
is defined as a heritable change in the DNA sequence, according to which the 
occurrence of random drug-induced mutational events leads to the formation of drug-
resistant cells from sensitive cells (Biedler and Spengler, 1994; Iwasa, 2006). 
‗Epigenetic‘ refers to the information contained in the chromatin rather than in the 
actual DNA sequence (Jaenisch and Bird, 2003) which is mediated via short RNAs. 
According to this hypothesis, the induction of epigenetic changes results in resistance 
to cytotoxic drugs (Baker and El-Osta, 2003; Glasspool et al., 2006). The absence of 
convincing evidence that genetic changes have a role in acquired clinical resistance 
following anti-cancer therapy undermines the genetic hypothesis (Glasspool et al., 
2006). 
In contrast, a number of studies have indicated substantial alterations of 
epigenetic elements in drug-resistant cancer cells, including changes in DNA 
methylation, histone modification and short RNA patterns (Fojo, 2007; Glasspool et 
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al., 2006; Teodoridis et al., 2004). The ‗karyotypic‘ hypothesis that refers to 
abnormalities in the number, form or structure of chromosomes (Duesberg et al., 
2007; Fojo, 2007; Glasspool et al., 2006; Iwasa et al., 2006; Teodoridis et al., 2004) is 
closely related to the epigenetic hypothesis since epigenetic changes are necessary 
precursors of karyotypic changes (Matarazzo et al., 2007; Wilson et al., 2007). 
Therefore, karyotypic changes may be considered as a consequence of a progression 
of epigenetic alterations and may serve as indirect evidence for the importance of 
epigenetic dysregulation in the acquisition of cancer drug resistance. 
Epigenetics is ―the study of mitotically and/or meiotically heritable changes in 
gene function that cannot be explained by changes in DNA sequence‖ (Russo et al., 
1996). In eukaryotic cells, epigenetic changes include DNA methylation and histone 
modifications (Hirst and Marra, 2008).  
Cytosine DNA methylation was the first epigenetic alteration identified; and 
currently it is the most widely studied epigenetic mechanism.  It is crucially important 
for the normal development, cell proliferation and proper maintenance of genome 
stability of a given organism (Baylin 2005; Baylin and Ohm, 2006; Jaenisch and Bird 
2003). 
DNA methylation occurs at the C5 position of cytosines that precede guanines 
and form the so-called CpGs (Bird, 2002; Weber and Schubeler, 2007). 
Approximately 1 % of all cytosines in the genome are methylated, which corresponds 
to 70-80 % of all CpGs (Ehrlich et al., 1982; Weber and Schubeler, 2007). CpGs are 
not randomly distributed in the genome but form CpG rich regions called ―CpG 
islands‖ (Antequera and Bird, 1993). Methylation of DNA is a transfer of a methyl 
group from the methyl donor S-adenosyl-methionine (SAM) to the carbon 5 position 
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of cytosine which is catalyzed by DNA methyltransferase enzymes (DNMT), 
DNMT1, DNMT3a and DNMT3b (Szyf et al., 2004; Teodoris et al., 2004). DNMT1 
functions primarily to maintain a methylation pattern after DNA replication (Vertino 
et al., 2002), while DNMT3a and DNMT3b act mainly as de novo methyltransferases 
establishing methylation patterns during development (Chen et al., 2003). CpG island 
methylation is associated with gene silencing (Jones et al., 1998). Loss of DNA 
methylation at CpGs was the first epigenetic change identified in cancer cells 
(Feinberg and Vogelstein, 1983).  
In breast cancer, there are two changes in a methylation pattern established: 
global hypomethylation and regional hypermethylation of promoter regions of certain 
genes (Szyf et al., 2004). There have been proposed three mechanisms to explain the 
contribution of DNA hypomethylation to cancer development: (a) an increase in 
genomic instability; (b) reactivation of transposable elements; and (c) loss of 
imprinting (Esteller, 2008). Hypomethylation could be possibly involved in activation 
of tumour promoting genes and pro-metastatic genes. Interestingly, along with global 
hypomethylation, cancer cell genomes are characterized by hypermethylation of the 
CpG islands localized in the active regions of tumour suppressor genes and 
microRNA genes (Hirst and Marra, 2008). Inactivation of tumour suppressor genes 
through hypermethylation of CpGs also plays a significant part in the process of 
carcinogenesis.  
Undoubtedly, changes in DNA methylation are not isolated events, and they occur 
in the context of global chromatin deregulation and altered histone modification levels 
(Jaenisch and Bird, 2003; Weidman et al., 2007).  Histone modifications, including 
acetylation, methylation, phosphorylation and ubiquitination, are important in the 
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transcriptional regulation (Jenuwein and Allis, 2001; Kovalchuk and Baulch, 2008; 
Weidman et al., 2007). Many histone modifications are stably maintained during the 
process of cell division. The acetylated histone tails lose their positive charge, reducing the 
affinity to negatively charged DNA,and leading to the relaxed chromatin packaging. 
Therefore, histone acetylation is linked to transcriptional activation, while histone 
deacetylation is an opposite repression event (Jenuwein and Allis, 2001). Histone 
methylation can result in different transcriptional consequences depending upon the type of 
residue affected (Cheung and Lau, 2005; Saha et al., 2006). Histone H3 lysine 9 
methylation is associated with chromatin compaction and gene silencing, while histone H3 
lysine 4 and lysine 27 methylation results in transcription activation and chromatin 
relaxation. Additionally, histone residues can be mono-, di- and tri-methylated, adding 
an enormous complexity to the yet unexplored histone code (Cheung and Lau, 2005; 
Saha et al., 2006; Weidman et al., 2007). It was recently shown that tumors undergo a 
massive loss of tri-methylation at lysine 20 of histone H4, which was  suggested to be 
a universal marker of malignant transformation (Fraga et al., 2005; Tryndyak et al., 
2006a; Tryndyak et al., 2006b; Fraga et al., 2005).  
Phosphorylation is another important histone modification (Sedelnikova, 
2003). One of the best-studied modifications is phosphorylation of histone H2AX. 
H2AX is a member of the H2A histone family. It becomes phosphorylated at serine 
139 (γH2AX) as one of the earliest cellular responses to double strand breaks (DSBs) 
(Pilch et al., 2003; Rogakou et al., 1998; Sedelnikova et al., 2003). γH2AX 
accumulates in the nucleus forming γH2AX foci; a direct correlation has been found 
between H2AX phosphorylation and the number of DSBs resulting from radiation 
(Celeste et al., 2003a). γH2AX is crucially important for the repair of DNA strand 
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breaks and for the maintenance of genome stability (Celeste et al., 2003b). Finally, 
epigenetic control can also be mediated by small regulatory RNAs (Bernstein and 
Allis, 2005). 
 
STRATEGIES FOR REVERSING DRUG RESISTANCE 
Drug resistance, no matter whether it is intrinsic or acquired, is the main 
problem hindering the success of chemotherapy. Conventional drugs have limited 
potential, but it seems that if drug resistance can be overcome, the spectrum of activity 
of drugs will be extended. Targeting a weak component in the drug response pathway 
could possibly reverse resistance cells back to their sensitive status. 
There are numerous ways of targeting chemoresistance (Fojo and Bates, 
2003). Each of them is based on either genetic or epigenetic strategies which can 
revert a malignant phenotype or enhance drug sensitivity, and such strategies are 
based on the knowledge about mechanisms of drug resistance. One of the first 
approaches for overcoming drug resistance was targeting ABC transporters (Tsuruo et 
al., 1983). ABC-mediated chemoresistance is based on reduction of intracellular drug 
levels. It leads to the reduction in the amount of drug that can reach the target and 
consequently to the reduced cytotoxicity. Such type of resistance effects almost every 
existing drug; therefore, the inhibitition of drug efflux could improve drug activity and 
block multi-drug resistance. The first strategy to inhibit Pgp-MDR1 relied on the 
identification of agents which compete with drugs for the pump. Such compounds are 
not cytotoxic; they act as inhibitors and could be easily identified because Pgp-MDR1 
could bind a vide variety of hydrophobic compounds (Ford and Hait, 1990). However, 
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Pgp is also expressed in several other tissues (liver, kidney, and colon) and plays an 
important physiological role in the excretion of toxins. Therefore, it is necessary to 
achieve a specific targeting of Pgp exclusively in cancer cells. 
Another strategy to overcome Pgp activity includes the use of hammerhead 
ribozymes against the MDR1 gene and MDR1-targeted antisense oligonucleotides 
(ASOs) (Dassow et al., 2000; Huesker et al., 2002). Hammerhead ribozymes are 
oligonucleotides with endoribonucleolytic cleavage activity (Irie et al., 1997), and 
they cleave specific mRNA molecules encoding genes responsible for drug resistance 
(Holm et al., 1994). The ability to target specific cells is considered to be the 
advantage of ribozymes. Gao et al., (2007) showed that reversal of drug resistance in 
breast adenocarcinoma cells can be achieved by anti-mdr1 ribozyme regulated by a 
tumor-specific MUC-1 promoter. In this case, the expression of ribozymes was 
limited to only breast cancer cells and did not affect normal cells. ASOs do not 
possess cleavage activity, but they recruit endonuclease RNAse H which destroys 
target mRNAs. Both ribozymes and ASOs are susceptible to degradation and can be 
recycled, so they can affect more mRNAs.  
A different strategy to modulate multidrug resistance is depletion of 
glutathione levels. Due to its reactivity and high intracellular concentrations, GSH is 
implicated in resistance to numerous drugs including anthracyclines (Lai et al., 1991). 
It has been shown that GSH depletion increased the sensitivity of MRP1-expressing 
but not MDR1-expressing cells, suggesting that GSH participates in MRP1-mediated 
anthracycline resistance (Benderra et al., 2000).  
Targeting apoptosis can also modulate drug resistance. Apoptosis is the 
outcome of interactions between pro- and anti-apoptotic regulators. The process of 
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apoptosis is very complex; therefore, there are many potential target sites for 
intervention. Suppression of proteins inhibiting apoptosis is approached by using 
antisense oligonucleotides (ASOs). ASOs are small 16-24 bp oligonucleotides 
composed of short sequences of single-stranded DNA complimentary to certain 
mRNAs (Tamm, et al., 2001). ASOs form heteroduplexes with mRNAs releasing 
RNAse H which destroys the mRNA strand. 
Such strategy was applied to target Bcl-2 overexpression, which is associated 
with chemoresistance (Klasa et al., 2002). ASOs have also been used to target TGFβ 
(Fakhrai, 1999) and glucose transporters (Chan et al., 1999) aimed to increase the rate 
of apoptosis upon chemotreatment.  
Chemoresistance is often acquired during treatment (Perez-Placencia and 
Duenas-Gonzalez, 2006). Therefore, chemotherapy should be studied at a global 
genomic and epigenomic level. It is already known that cancer cells do have multiple 
genetic defects such as deletions, duplications, translocations, etc., as well as 
epigenetic aberrations which include numerous alterations in DNA and histone 
modifications (Baylin and Ohm, 2006; Weinstein, 2000). Because multi-drug 
resistance is driven by so many mechanisms described in previous paragraphs, it 
would require changes in expression of a very large number of genes. In this regard, it 
is very hard to explain a chemoresistant phenotype by genetic changes, instead 
epigenetic changes could rapidly affect expression of multiple genes shortly after 
chemotherapeutical treatment (Glasspool, et al., 2006). 
When considering prospects for the reversal of drug resistance, it becomes 
obvious that in contrast to genetic defects, epigenetic alterations are reversible and 
therefore may be much easier to target. Furthermore, the role of epigenetic control of 
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gene expression in chemoresistance is highlighted in many studies; therefore, many 
new approaches to reverse drug resistance are based on altering the cellular epigenetic 
status (Brown and Strathdee, 2002). 
Many aberrantly methylated genes were found to be involved in determining 
chemoresistance. For example, methylation of DNA repair genes such as MGMT and 
FANCF leads to inactivation of DNA repair and provides chemosensitivity, whereas 
methylation of pro-apoptotic genes such as MLH1 and APAF1 would confer 
resistance (Esteller et al., 2000; Glasspool et al., 2006).  
It has been shown by Gloria and colleagues that the MDR1 promoter gene is 
highly hypermethylated in drug sensitive MCF-7 human breast cancer cells and, 
therefore they lack the expression of MDR1, while an adriamycin (doxorubicin)-
resistant variant of the same cells (MCF-7/ADR) showed a low methylation status of 
MDR1 and high levels of Pgp-MDR1 protein (David et al., 2004). Similar evidence 
for the role of hypomethylation of the MDR1 promoter in the development of 
chemoresistance was provided by Chekhun and colleagues. They have reported a 
significant decrease in methylation of promoters of MDR1, glutathione-S-transferase 
(GST ), O6-methylguanine DNA methyltransferase (MGMT) and urokinase (Upa) 
genes in doxorubicin resistant MCF7/DOX cells as compared to sensitive NCF-7 cells 
(Chekhun et al., 2006). 
Other classes of epigenetic modifying agents include inhibitors of DNA 
methyltransferases (DNMT). An inhibitor of DNMT1, 5-aza-2‘deoxycytidine 
(decitabine), forms irreversible covalent bonds with DNMT1 after its incorporation 
into DNA and induces degradation of DNMT1 (Christman, 2002). Several other 
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derivatives of 2‘-deoxycytidine such as 5-azadcytidine (5-azaC), arabinosyl-5-
azacytosine (fazarabine) and dihydro-5-azacytidine (DHAC) are demethylating agents 
that have been proposed to have anti-tumour properties since they can activate 
expression of epigenetically silenced genes (Arnold, et all., 2003). It has been shown 
that the addition of these agents can induce sensitivity of cells to cisplatin, epirubicin 
and temozolomide (Plumb et al., 2000). 5-azadcytidine was also proved to re-express 
the MLH1 gene by its promoter methylation. MLH1 is a key component of mismatch 
repair, and as it was mentioned previously, loss of MMR results in resistance to 
cisplatin and doxorubicin in breast cancer cells (Plumb et al., 2000). Pakneshan and 
colleagues showed that the addition of a methylating agent S-adenosyl-methionine 
(AdoMet) can hypermethylate and inhibit expression of urokinase (uPA) which is 
expressed in highly invasive cancer cells (Pakneshan et al., 2004). 
These studies confirm the possibility of targeting epigenetic modifications to 
concur multiple chemoresistance mechanisms. It could be expected that agents 
targeting DNA methylation would revert the epigenetic status and therefore induce 
sensitivity of breast cancer cells to chemotherapy agents, including doxorubicin. 
Taken together, chemoresistance can be reversed by epigenetic therapy either by 
reversing hypermethylation of tumour suppressor genes or by achieving 
hypermethylation of protooncogenes.  
The main agents that could cause changes in histone modification patterns of 
drug-resistant cells are those that inhibit histone deacetylases (HDACs). HDAC 
inhibitors can reactivate genes involved in cell cycle control or apoptotic signalling, 
thereby inhibiting proliferation (Donadelli et al., 2003). In addition, treatment with 
HDAC inhibitors can sensitize cancer cells to irradiation (Camphausen et al., 2004).  
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In sum, from the existing literature we have learned that: 
 Doxorubicin is an anthracycline drug frequently used in curative-intent 
adjuvant and palliative treatment of metastatic breast cancer. Although 
doxorubicin is among the most active agents in breast cancer treatment, many 
patients will experience a relapse.  
 Drug resistant cancer cells often fail to respond to cytotoxic radiotherapy and 
develop a multi-drug resistant phenotype; however, the data on radiation 
responses of chemoresistant tumors is contradictory. On the one hand, some 
studies suggest significant benefits of chemo- and radiotherapy combination 
for management of breast cancer. On the other hand, there is an evidence that 
chemotherapy as ―induction therapy before radiotherapy‖ has no significant 
additive anti-tumor effects.  
 Breast tumors tend to resist and reoccur after the aforementioned treatments.  
Acquired treatment resistance is a multi-factorial phenomenon involving 
multiple mechanisms and processes including: decreased uptake of drugs; 
alterations in cell cycle and signal transduction pathways; increased repair of 
DNA damage; reduced apoptosis; increased efflux of hydrophobic drugs; and 
DNA damage tolerance. Nevertheless, the exact nature and mechanisms of 
radiation responses of chemoresistant tumor cells still remain obscure. 
 
PRESENT STUDY: OBJECTIVES AND HYPOTHESES 
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The main goal of the current thesis is to investigate molecular mechanisms of 
radiation responses of MCF-7 breast adenocarcinoma cells resistant to doxorubicin 
and propose a strategy to modify/improve their radiation sensitivity.  
 Guiding Hypothesis:  
 
Based on evidence from the existing literature, we hypothesize that 
doxorubicin-resistant MCF-7 cells (MCF-7/DOX) are much more resistant to 
radiation exposure than their drug-sensitive analogues (MCF-7 cells).  We think that 
differences in radiation responses are due to different susceptability of MCF-7 and 
MCF-7/DOX cells to radiation-induced DNA damage and apoptosis.  We suggest that 
the latter phenomenon is epigenetically mediated via a different DNA methylation 
status of MCF-7 and MCF-7/DOX cells. Therefore, we predict that modifying the 
epigenetic status of MCF-7/DOX cells will alter their radiation responsiveness. 
The following experiments were conducted to achieve the goal and test the 
proposed hypotheses: 
Experiment 1: To analyze molecular mechanisms of radiation resistance in 
doxorubicin-resistant breast adenocarcinoma cells. 
Experiment 2: To test whether epigenetic therapy aimed to modify the DNA 
methylation status will improve radiation sensitivity of MCF-7/DOX cells. 
 
The outcomes of these experiments are presented as chapters of this thesis. 
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CHAPTER 2: MOLECULAR MECHANISMS OF RADIATION 
RESISTANCE IN DOXORUBICIN-RESISTANT BREAST 
ADENOCARCINOMA CELLS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 has been submitted in its entirety: 
Luzhna L, Golubov A, Pogribny I and Kovalchuk O. Molecular mechanisms of 
radiation resistance in doxorubicin-resistant breast adenocarcinoma cells. DNA Repair 
(in review) 
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ABSTRACT 
 
Positive response to breast cancer treatment is largely dependant on the 
successful combination of anticancer treatment modalities such as chemo- and 
radiation therapy. Unfortunately, chemotherapy resistance occurs frequently. 
Furthermore, drug resistant tumors can become unresponsive to the use of other 
antitumor therapies, and often fail to respond to radiation therapy. The molecular 
mechanisms underlying the radiation responses of chemoresistant cells and tumors are 
not well understood.  
In the present study, we analyzed the effect of ionizing radiation on MCF-7 
human breast adenocarcinoma cells and their doxorubicin resistant variant MCF-
7/DOX. The results demonstrate that drug resistant MCF-7/DOX cells were less 
susceptible to radiation-induced DNA damage and apoptosis. This was evidenced by 
lower levels of γH2AX foci upon irradiation and altered levels of DNA repair 
proteins, including pATM, KU70 and RAD51. Additionally, MCF-7/DOX drug-
resistant cells harbored DNA polymerases with significantly lower fidelity. In 
summary, our study revealed that drug-resistant MCF-7/DOX cells have high DNA 
repair potential and low fidelity of DNA polymerases seemingly sacrificing specificity 
and efficiency to gain higher survival potential. In the long run this may lead to an 
increased probability of accumulation of mutations and further to the development of 
even more pronounced resistance phenotype.   
Therefore, this study may provide a roadmap for the analysis of the roles of 
DNA repair function and effectiveness and apoptosis in response to radiation, 
chemotherapy and combinations of both treatment modalities. 
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INTRODUCTION 
Systemic chemotherapy is an important breast cancer treatment modality and 
its effectiveness has significantly improved over the past decade (Guarneri and Conte, 
2004). Notwithstanding, the development of cancer cells resistant to chemotherapeutic 
agents is a major clinical obstacle in the successful treatment of breast cancer 
(Lehnert, 1996; Szakacs et al., 2006). Understanding the mechanisms underlying drug 
resistance development and predisposition is critical to saving lives. 
Overall, acquired drug resistance is a multi-factorial phenomenon, involving 
multiple mechanisms and processes (Lehnert, 1996; Szakacs et al., 2006; Fojo, 2007; 
O'Driscoll and Clynes, 2006) including: decreased uptake of drugs (Gottesman, 2002); 
alterations in cell cycle and signal transduction pathways (Pommier et al., 2004; 
Stavrovskaya, 2000); increased repair of DNA damage (Karran, 2001); reduced 
apoptosis (Pommier et al., 2004; Rixe and Foho, 2007; Hickman, 1996); increased 
efflux of hydrophobic drugs (O‘Driscoll and Clynes, 2006; Gottesman, 2002; 
Stavrovskaya, 2000; Gottesman and Ling, 2006; Modok et al., 2006); and DNA 
damage tolerance (Karran, 2001). Resistance to individual chemotherapeutic agents 
usually occurs through alterations in the targets for these drugs, but broad resistance 
can also occur affecting the utility of a variety of diverse and unrelated antitumor 
drugs with different chemical structures and different mechanisms of action 
(O‘Driscoll and Clynes, 2006; Gottesman and Ling, 2006; Coley, 2008; Gonzalez-
Angulo et al., 2007; Petrelli and Giordano, 2008). Apoptosis avoidance is one of the 
key mechanisms underlying multiple drug resistance phenotype (Pommier et al., 
2004; Rixe and Fojo, 2007; Hickman, 1996; Chekhun et al., 2007). 
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Doxorubicin is an anthracycline drug frequently used in curative-intent 
adjuvant and palliative treatment of metastatic breast cancer (Dean-Colomb and 
Esteva, 2008). Although doxorubicin is among the most active agents in breast cancer 
treatment, many patients will experience a relapse. Furthermore, approximately half of 
metastatic breast cancer patients will fail to respond to doxorubicin entirely, and the 
majority of those showing initial benefit will subsequently demonstrate acquired 
clinical resistance, as demonstrated by tumor growth despite ongoing anthracycline 
therapy (Dean-Colomb and Esteva, 2008). Importantly, it has also been reported that 
drug resistant cancer cells may fail to respond to cytotoxic radiotherapy and may 
develop a multi-drug resistant phenotype (Ozols et al., 1988; Shimm et al., 1988; 
Belli, 1989; Lehnert et al., 1989; Lehnert et al., 1990; Alaoui-Jamali et al., 1992; 
Miller et al., 1992; Zhang et al., 1992; Lehnert et al., 1994). However, the data on the 
radiation responses of chemoresistant tumors is contradictory. For instance, some 
clinical studies suggest significant benefits of combination of chemo- and 
radiotherapy for management of breast cancer (Liang et al., 2003). On the other hand, 
there is proof that chemotherapy as ―induction therapy before radiotherapy‖ has no 
significant additive anti-tumor effects (Koukourakis et al., 1999). Breast tumors tend 
to resist and reoccur after the aforementioned treatments (Gewirtz, 2000). The exact 
nature and mechanisms of radiation responses of chemoresistant tumor cells remain 
obscure.  
One of the key features of cancer cells resistant to therapeutic agents is their 
associated resistance to apoptotic cell death (Pommier et al., 2004). Chemoresistant 
cells and tumors harbor a strong capacity to withstand and avoid apoptosis upon 
chemotherapy treatment (Pommier et al., 2004; Reinhold et al., 2003). Ionizing 
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radiation (IR) exposure is known to induce apoptosis in exposed cells, yet little is 
known about the status of IR-induced apoptosis in drug resistant cell lines. 
In this study we analyze the cellular and molecular mechanisms of radiation 
responses in MCF-7 breast adenocarcinoma cells and their derivative line that is 
resistant to doxorubicin (MCF-7/DOX). Here we for the first time show that MCF-
7/DOX cells while harboring an elevated potential to repair radiation-induced DNA 
damage also have a significantly decreased fidelity of DNA polymerases and low 
levels of radiation-induced apoptosis.  
 
MATERIALS AND METHODS 
Cell lines and cell culture conditions 
MCF-7 and MCF-7/DOX multidrug-resistant human breast adenocarcinoma 
cell lines were previously developed and described (Chekhun et al., 2007; Kovalchuk 
et al., 2008). Cells were grown and maintained in Dulbecco‘s Modified Eagle‘s 
Medium (DMEM /F-12) with 2.5 mM L-Glutamine, without HEPES and Phenol Red 
(HyClone, Logan, UT), supplemented with 10% heat-inactivated fetal bovine serum 
(HyClone, Logan, UT), in the presence of antibiotics 100 U/mL penicillin and 100 
µg/mL streptomycin (Sigma-Aldrich Chemical Co., St. Louis, MO) in 5% CO2 
atmosphere at 37 ºC. Cells were harvested for analyses by trypsinization (Chekhun et 
al., 2007; Kovalchuk et al., 2008). 
Irradiation conditions 
Cells were irradiated at the confluency of 60% in DMEM. Two radiation doses 
(0.5 Gy and 5 Gy, 90 kV, 5 mA) were applied in order to check the cellular radiation 
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responses. Un-irradiated cells served as control. Cells were harvested 30 minutes, 24 
hours and 48 hours after irradiation. All cells were tested in triplicate. Experiments 
were independently reproduced twice. 
Immunofluorescence  
For immunocytochemical analysis, cells were grown on Lab-Tek chambered 
2-well slides (Nulge Nunc International Corp., Naperville, IL) and irradiated. After 
irradiation, the cells were fixed in 4% paraformaldehyde in PBS for 20 minutes, 
permeabilized with 70% ethanol at -20 °C and washed in PBS containing 0.1% 
TRITON-X100. Blocking was done in 8% BSA in PBS for 1 hour. For 
immunocytochemical detection, cells were incubated for 2 hours at room temperature 
using the following antibodies: anti-γH2AX (Ser 139) rabbit antibodies (1:100, Cell 
Signaling Technology Inc., Danvers, MA), anti-RAD51 rabbit antibodies, anti-pATM, 
and anti-KU70 mouse antibodies (1:100, Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA). Afterwards, cells were rinsed and incubated with 1:500 diluted secondary 
antibodies (goat anti-rabbit IgG Alexa Fluor 488, goat anti-mouse IgG Alexa Fluor 
546 and goat anti-mouse IgG Alexa Fluor 488, Invitrogen Molecular Probes, Eugene, 
OR) at 37 ºC for 1 hour. Cell nuclei were counterstained with 0.1 mg/mL 4‘,6-
diamidino-2-phenylindole dihydrochloride (DAPI) (Sigma-Aldrich Chemical Co., St. 
Louis, MO) for 30 minutes at 37 ºC. Slides were mounted with anti-fade fluorescence 
medium prepared from 1,4-diazabicyclo[2.2.2]octane (DABCO), polyvinyl alcohol 
and glycerol and analyzed with Zeiss epifluorescent microscope.  
The number of γH2AX foci per cell was counted in at least 400 cells from 
each cell group, as previously described (Sedelnikova and Bonner, 2006). γH2AX 
levels were represented as the mean ± SE; P ≤ 0.05. 
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Western immunoblotting 
The cells from culture flasks were harvested, washed in PBS, lysed and 
sonicated in 0.2 mL of 1% sodium dodecyl sulphate (SDS) on ice. The lysates were 
cleared by centrifugation, and the supernatants collected and boiled at 95 ºC for 5 
minutes. Protein content was determined with the Bradford protein determination 
assay (BioRad, Hercules, CA). Equal amounts of lysate protein (20 µg/10 µL) were 
subsequently run on 10-12% SDS-polyacrylamide gels and transferred to PVDF 
membranes (GE Healthcare, Baie d‘Urfé, Québec).  
Western immunoblotting was conducted with well-established protocols 
(Kovalchuk et al., 2008; Tryndyak et al., 2006). Membranes were incubated with 
antibodies against goat anti-polymerase iota, mouse anti-polymerase epsilon (1:1000, 
Santa Cruz Biotechnology, Inc., Santa Cruz, CA ), mouse anti-polymerase beta and 
rabbit anti-polymerase delta (1:500 dilution, Abcam Inc., Cambridge, MA). Antibody 
binding was revealed by incubation with horseradish peroxidase-conjugated 
secondary antibodies (GE Healthcare, Piscataway, NJ) and the ECL Plus 
immunoblotting detection system (GE Healthcare, Piscataway, NJ). 
Chemiluminescence was detected by Biomax MR films (Eastman Kodak, New 
Haven, CT). Unaltered PVDF membranes were stained with Coomassie Blue 
(BioRad, Hercules, CA) and the intensity of the Mr 50 000 protein band was assessed 
as a loading control. Signals were quantified using NIH ImageJ 1.63 Software and 
normalized to both actin and the Mr 50 000 protein band, which gave consistent 
results (values relative to Mr 50 000 are plotted).  
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Analysis of DNA polymerase fidelity in MCF-7 and MCF-7/DOX cells 
The DNA polymerase fidelity assay allows to determine activity of 
polymerases on damaged DNA and the quality of repair synthesis (Gening et al., 
2004). The assay employs a FAM-labeled 15bp primer as a component of the 
substrate. Its oligonucleotide can be revealed on a gel. In the assay, different 
deoxyribonucleotides are added to the reaction mixture to check the ability of 
polymerases to incorporate the correct and incorrect dNTPs into the template. Any 
increase in primer weight upon incorporation would indicate higher DNA polymerase 
activity, while a decrease is associated with exonuclease activity. The efficiency of 
misincorporation is associated with changes in DNA polymerase fidelity.  
Substrate (template/primer complex). In order to produce the substrate for 
assay, FAM-labeled 15bp primer was annealed with 30bp template (both were PAGE 
purified). 
Template: AG030-PAGE 
5‘ - TCATCGAGCATGATCACGTCGTGACTGGGA – 3‘ 
Primer: AG031-PAGE 
5‘ – FAM – TCCCAGTCACGACGT – 3‘ 
The reaction was performed in 1 M Tris-HCl, pH 8.0, β-mercaptoethanol, BSA 
(100× NEB), 100 µM primer and 100 µM template, incubated at 95 ºC for 5 minutes 
and slowly cooled down at room temperature. 
Cell extracts. MCF-7 and MCF-7/DOX control and irradiated (harvested 24 
hours after 5 Gy X-ray treatment) cells were harvested, washed in 10 mL of 1x PBS, 
resuspended and sonicated in 200 µL of PBS (350 W, 5 x 10 min) and centrifuged at 4 
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ºC for 10 minutes, 14,000 g. Total protein concentration in samples was determined 
by Bradford Assay (BioRad, Hercules, CA). 
DNA polymerase fidelity assay was carried out according to Gening and 
colleagues (Gening et al., 2004). The reaction was performed at 37 ºC for 15 minutes 
and quickly frozen afterwards. Reaction mixture contained 50 mM Tris-HCl, pH 8.0, 
5 mM MgCl2, 1 mM DTT, 70 µg of the tested lysate protein, template/primer complex 
and 2 mM dNTP. When the reaction was stopped, 5 µL of each sample was mixed 
with 10 µL of loading buffer (95% formamide, 50 mM EDTA, 0.05% bromophenol 
blue), incubated at 95 ºC for 3 minutes and cooled down on ice. Reaction products 
were separated in 20% polyacrylamide gel in the presence of 8 M urea in Tris-borate 
buffer at 750 V. Afterwards PAGE gels were scanned using Typhoon 9410 imager 
(excitation 488 nm, emission filter 520 BP 40, PMT 620 V, resolution 50 µm).  
Annexin V assay  
For early detection of apoptosis, Annexin V-FITC Apoptosis Detection Kit I 
(BD Biosciences, San Jose, CA) was used according to the manufacturer‘s protocol. 
Cells were grown on 75 cm² cell culture flasks and irradiated as previously described 
(section 2.2). The analysis was performed 24 and 48 hours after radiation exposure. 
Cells were harvested, washed with PBS, resuspended in 1X binding buffer, stained 
with Annexin V and propidium iodide for 15 min at 25 ºC in the dark and analyzed by 
flow cytometry within one hour at the Flow Cytometry Core Facility (University of 
Calgary, Calgary, AB). The results were represented as percentage of gated Annexin 
V positive cells. 
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Statistical analysis 
Statistical analysis was performed using MS Excel 2007 and JMP5 software 
packages. 
 
RESULTS  
Radiation-induced apoptosis in MCF-7 breast adenocarcinoma cells and their 
drug-resistant counterpart MCF-7/DOX cells 
In this study, we characterized and compared the responses of the MCF-7 
breast adenocarcinoma line and its doxorubicin-resistant variant (MCF-7/DOX) 
(Chekhun et al, 2007; Kovalchuk et al., 2008) to ionizing radiation (IR) in vitro. IR 
exposure is known to induce apoptotic cell death in irradiated cells. Early apoptosis is 
characterized by various changes in the cellular plasma membrane, the main of which 
is the translocation of phosphatidylserine (PS) from the inner layer to the surface of 
the membrane. Annexin V possesses a high affinity to PS and this allows for early 
detection of apoptotic changes (Vermes et al., 1995). Here we analyzed IR-induced 
apoptosis using an Annexin V assay. 
Figure 2.0 shows that MCF-7 cells began to undergo early apoptosis 24 hours 
after irradiation (Figure 2.0). We found a 2- and 2.5-fold increase in Annexin V 
positive cells 24 hours after exposure to 0.5 and 5 Gy of X-rays, respectively. The 
percentage of MCF-7 cells in early apoptosis returned to control level by 48 hours, 
however, the number of dead cells increased at this time point (Figure 2.0). Such 
changes may indicate that cells which were undergoing early apoptosis 24 hours after 
irradiation were dead by 48 hours. In contrast, MCF-7/DOX resistant cells showed 
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apoptotic response only 48 hours after treatment with the high IR dose (5 Gy). The 
9.1-fold increase in Annexin V positive cells was reached 48 hours after X-ray 
treatment of MCF-7/DOX cells (Figure 2.1).  
Radiation-induced DNA damage in MCF-7 and MCF-7/DOX  
Next, we analyzed the mechanisms associated with such significant 
differences in IR-induced apoptotic response in MCF-7 and MCF-7/DOX cells. IR is a 
potent DNA damaging agent capable of inducing cross linking, nucleotide base 
damage and, most importantly, single and double strand breaks (DSBs), which are 
well-known inducers of apoptosis (Little, 2000; Huang et al., 2003). Therefore, we 
analyzed the levels of IR-induced DNA damage in MCF-7 and MCF-7/DOX cells by 
detecting γH2AX foci, a well accepted indicator of DNA strand breaks (Bonner et al., 
2008). 
Figure 2.2 shows that both IR doses, 0.5 Gy and 5 Gy, led to the formation of 
γH2AX foci in MCF-7 and MCF-7/DOX cells. However, MCF-7/DOX cells were 
much less sensitive to IR than MCF-7 cells (Figure 2.2). Specifically, irradiation of 
MCF-7 cells caused significant 2.6 and 8.5 times increases in the levels of γH2AX 
foci, from 3.14±0.22 foci per cell in control to 8.23±0.53 and 26.70±1.02 foci per 
cells, 30 minutes after 0.5 Gy and 5 Gy treatments, respectively (Figure 2.2 A). 
γH2AX foci induced by 0.5 Gy of X-rays disappeared 48 hours after irradiation, 
indicating efficient DNA repair. While application of 5 Gy of X-rays led to persistent 
elevation of γH2AX foci as detected 48 hours after exposure.  
In MCF-7/DOX cells radiation exposure led to significant 1.9 and 6.0 times 
increases in the levels of γH2AX foci, from 1.83±0.2 foci per cell in control to 
3.49±0.15 and 10.9±0.44 foci per cell after 0.5 Gy and 5 Gy treatments, respectively 
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(Figure 2.2 B). The levels γH2AX foci significantly decreased 24 and 48 hours after 
irradiation. 
Most importantly, the  levels of  γH2AX foci in MCF-7 cells were in all cases 
significantly different from the levels seen at the corresponding time-points in MCF-
7/DOX cells (Figure 2.2). 
DNA repair machinery in MCF-7 and MCF-7/DOX cells 
Apparent differences in the levels of IR-induced DNA damage between MCF-
7 and MCF-7/DOX cells have logically led us to question how the resistant cells 
repair the DNA lesions. In mammalian cells, two mechanisms exist to repair DSBs: 
homologous recombination (HR) and non-homologous end joining (NHEJ) (West, 
2003; McGlynn and Lloyd, 2002; Helleday, 2003; Hoeijmakers, 2001).  
The key component for both mechanisms is a serine/threonine specific protein 
kinase – ATM. Phosphorylation of ATM is necessary for DSB repair (Bonner et al., 
2008; Chowdhury et al., 2005). Therefore, we analyzed the level of phosphorylated 
ATM (pATM) in MCF-7 and MCF-7/DOX cell lines after irradiation.  
Overall, the level of pATM was higher in MCF-7/DOX cells (Figure 2.3). 
Interestingly, the subcellular localization of the protein was different in MCF-7 and 
MCF-7/DOX cell lines (Figure 2.4). For example, in MCF-7 cells, pATM was 
detected as nuclear foci (Figure 2.4). The number of pATM nuclear foci in MCF-7 
cells increased after irradiation. The dynamics of pATM expression was similar to that 
of γH2AX (Figure 2.2 A).  
In MCF-7/DOX resistant cells, no pATM foci were observed, and the protein 
was localized in both nucleus and cytoplasm. Yet, the general level of pATM in MCF-
7/DOX cells was higher than in the MCF-7 cells (Figure 2.3 and Figure 2.4).  
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With evidence of different levels of γH2AX and pATM in MCF-7 and MCF-
7/DOX cells, we then asked if HR or NHEJ-related proteins were differentially 
induced in these cell lines after irradiation. RAD51 is a key protein essential for repair 
of DSBs via HR in mammals (Lundin et al., 2003). KU70 is a key participant in the 
NHEJ pathway to repair DSBs (Hoeijmakers, 2001; Jin and Weaver, 1997). 
Immunocytochemistry was performed to analyze the levels of RAD51 and 
KU70 in MCF-7 and MCF-7/DOX cells after irradiation. We found that the 
expression level of RAD51 increased after irradiation in both cell lines (Figure 2.5), 
but the highest level was observed in MCF-7/DOX cells after exposure to 5 Gy of X-
rays (Figure 2.5).  
Interestingly, MCF-7 cells expressed relatively high levels of KU70 prior to 
irradiation and an abundant amount of the protein was found after exposure (Figure 
2.6). Contrarily, KU70 levels were almost undetectable in the un-irradiated MCF-
7/DOX cells, and only exposure to 5 Gy of X-rays resulted in a noticeable up-
regulation of KU70 levels (Figure 2.6).  
Analysis of fidelity and expression of DNA polymerases in MCF-7 and MCF-
7/DOX cells 
All types of DNA repair involve re-synthesis of DNA to replace damaged 
strands. To uncover any correlation between the dynamics of induction and repair of 
IR-induced DNA damage, we studied the fidelity of the DNA polymerase pool in the 
cell lysates from MCF-7 and MCF-7/DOX (Figure 2.7). Because doxorubicin resistant 
MCF-7/DOX cells manage to deal with DNA damage faster than MCF-7 cells, we 
hypothesized that DNA polymerases may be more active in the resistant cells. We 
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analyzed the DNA polymerase fidelity in the MCF-7 and MCF-7/DOX (Gening et al., 
2004).  
dNTPs were added to the mixture containing the template and extracts of 
unirradiated or irradiated MCF-7 or MCF-7/DOX cells and the incorporation patterns 
were analyzed. According to the template sequence (see section Materials and 
Methods), the next nucleotide to be inserted was dGTP. In the case when only dGTP 
was in the reaction mixture, we obtained a 16bp gel band with higher intensity in 
MCF-7/DOX, moreover, the band corresponding to irradiated MCF-7/DOX had the 
highest intensity (Figure 2.7). The observed difference may be explained by higher 
DNA polymerase activity or an increased amount of polymerases in resistant cells.  
Furthermore, as shown in figure 2.7, MCF-7/DOX had higher level of 
misincorporation of dATPs which means that DNA polymerase specificity or fidelity 
is lower in the drug-resistant cells. We did not observe incorporation of dTTP and 
dCTP. Therefore, we concluded that ATP is the most common wrong nucleotide to be 
inserted instead of GTP by the low fidelity polymerases to continue synthesis in MCF-
7 cells. When adding both dGTPs and dATPs or all dNTPs to the samples, we 
obtained 16- and 17bp bands and completed synthesis respectively (Figure 2.7). In all 
the cases the activity of the polymerases was higher in the MCF-7/DOX resistant cell 
line.  
At the same time, we observed more intensive DNA cleavage in MCF-7 cells 
due to a significant exonuclease activity. The excision of wrong nucleotides by 
exonucleases reduces mismatches. The control sample did not contain any dNTPs and 
no bands with a weight higher than 15bp were observed (Figure 2.7). The negative 
control contained all dNTPs and EDTA (to inactivate all metal-using enzymes). In 
 44 
such conditions, the activity of exonucleases was lower and the intensity of all the 
bands was the same. Both controls indicated that there were no endogenous 
oligonucleotides observed on the gels (Figure 2.7). 
In sum, we concluded that irradiated and un-irradiated MCF-7/DOX cells 
exhibited significantly higher processivity and significantly lower fidelity of 
polymerases.  
This may be due to higher levels of polymerase expression. We therefore 
analyzed the levels of polymerases δ, ε , β and ι in MCF-7 and MCF-7/DOX cells.  
The expression level of both polymerases δ and ε were found to be higher in 
MCF-7 cells (Figure 2.8). Furthermore, the level of DNA polymerase δ was slightly 
increased in doxorubicin-resistant MCF-7/DOX cells after radiation exposure.  
Two other polymerases – β and ι were highly expressed in MCF-7/DOX. 
While polymerase β level was much lower in MCF-7 cells, than in MCF-7/DOX, 
polymerase ι was not detected at all (Figure 2.8). DNA polymerase ι was recently 
discovered as a polymerase that catalyses error-prone DNA synthesis. It promotes 
replication of damaged DNA by misincorporating deoxynucleotides opposite DNA 
lesions (Bebenek and Kunkel, 2004; Shcherbakova et al, 2003). 
The altered levels of DNA polymerases may explain, at least in part, the higher 
processivity and lower fidelity seen in MCF-7/DOX cells. 
 
DISCUSSION 
Relapse risk in breast cancer is largely dependent on the combination of 
anticancer treatment modalities. Anthracycline chemotherapy is increasingly used for 
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treating locally advanced breast cancer and hormone-resistant metastatic breast tumors 
(Guarneri and Conte, 2004; Gonzalez-Angulo et al., 2007). 
Unfortunately, resistance to chemotherapy occurs frequently (Gonzalez-
Angulo, et al., 2007). Drug resistant tumors often become unresponsive to the use of 
other antitumor therapies, acquire multidrug resistance and often fail to respond to 
radiation therapy (Stavrovskaya, 2000). Frequently, the use of chemotherapy drugs as 
radiation sensitizers fails due to unknown reasons (Liang et al., 2003; Koukourakis et 
al., 1999). Overall, the data on the radiation response of drug resistant cells is scarce.  
Doxorubicin is widely used in curative-intent adjuvant breast cancer therapy 
(Fornari et al., 1994). Mechanistically, doxorubicin, an anthracycline antibiotic, 
intercalates DNA and inhibits the progression of the enzyme topoisomerase 2α 
(Top2A) (Fornari et al., 1994). Functionally, it stabilizes the Top2A complex after it 
has broken the DNA chain, preventing DNA resealing and thereby blocking 
replication (Fortune and Osheroff, 2000). Therefore, because doxorubicin treatment 
leads to induction of strand breaks, we hypothesized that cells exposed to doxorubicin 
for a prolonged time could develop mechanisms to effectively repair DSBs and 
therefore avoid drug-induced apoptosis. These mechanisms may consequently help 
drug resistant cells to withstand the effects of other treatment modalities that induce 
DNA strand breaks as the main mechanism of their cell-killing action. 
Therefore, in this study we assessed the levels of IR-induced apoptosis in 
MCF-7 and MCF-7/DOX cells. We noted that drug resistant cells were significantly 
less susceptible to IR-induced apoptosis than their resistant counterparts. Aiming to 
explain this apparent discrepancy in the levels of IR-induced apoptosis, we studied 
formation and repair of DNA DSBs, as seen through the induction of γH2AX foci in 
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MCF-7 and MCF-7/DOX cells after IR exposure. Importantly, the background 
number of γH2AX foci in untreated MCF-7 cells correlated with previous data from 
other investigators (Sedelnikova and Bonner, 2006).  
γH2AX foci appear in the nuclei within 1 minute after irradiation and reach 
their maximum number by 30 min to 1 hour. Afterwards, the number of γH2AX foci 
reduces due to repair processes (Bonner et al., 2008; Banath et al., 2004). Our assay 
showed that non-resistant MCF-7 cells are more radiosensitive (Figure 2.2). MCF-7 
cells were not able to completely repair DNA damages after high dose (5 Gy) 
treatment and even after 48 hours the residual amount of foci was very high. In 
contrast, drug-resistant MCF-7/DOX cells did not accumulate a lot of damage after 
low dose (0.5 Gy) treatment. The maximum number of foci was observed 30 minutes 
after 5 Gy X-ray exposure and was significantly lower than the number of foci 
detected in MCF-7 cells at this dose. Moreover, all DNA damage in the drug resistant 
MCF-7/DOX cells was repaired by 48 hours (Figure 2.2). Currently, it is thought that 
γH2AX recruits proteins to repair DNA damage, and γH2AX is dephosporylated after 
repair is complete (Chowdhury et al., 2005). Therefore, we assume that the faster foci 
disappear, the higher the DNA repair activity in the cells.  
DSBs can be repaired by two major mechanisms: homologous recombination 
(HR) and non-homologous end joining (NHEJ) (Hoeijmakers, 2001; Hoeijmakers, 
2001; Jeggo and Lobrich, 2006). HR allows cells to use the undamaged sister 
chromatid or the homologous chromosome as a template for repair and thus is 
considered error-free (West, 2003; McGlynn and Lloyd, 2002; Helleday, 2003; 
Hoeijmakers, 2001; Hoeijmakers, 2001). The error-free HR is controlled by RAD51 
protein (West, 2003; Lundin, 2003; Baumann and West, 1998; Dudas and Chovanec, 
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2004). RAD51 binds to single-stranded DNA and forms a nucleoprotein filament that 
catalyses homology searching, strand pairing, and strand exchange (Baumann and 
West, 1998; Benson et al., 1998). NHEJ is a fast, yet error-prone process of linking 
broken DNA ends together without reference to accurate base pairing (Hoeijmakers, 
2001; Hoeijmakers, 2001). This DNA repair mechanism is most common in 
mammalian cells and requires a DNA-binding component – a heterodimer of KU70 
and KU80 proteins (Hoeijmakers, 2001; Jin and Weaver, 1997). A crucial signalling 
component for both pathways is the protein kinase ATM. ATM coordinates DNA 
repair by phosphorylating the downstream proteins involved in the actual repair 
(Goodarzi et al., 2003). Activity of ATM is increased two- to three-fold after exposure 
to IR (Goodarzi, 2004). Such an increase in activity of ATM is thought to occur due to 
autophosphorylation of serine-1981 (Goodarzi, 2004). Our study showed that MCF-7 
and drug-resistant MCF-7/DOX cell lines have different profiles of the 
aforementioned DNA repair proteins. Although both cell lines exhibited elevated 
levels of pATM, RAD51 and KU70 after exposure, the initial level of these proteins 
were different (Figure 2.3, Figure 2.4, Figure 2.5 and Figure 2.6). We found that 
MCF-7 cells express higher level of KU70 which is a key protein for NHEJ, while in 
doxorubicin-resistant MCF-7/DOX cells the elevation of RAD51 could contribute to 
the HR-mediated DNA repair. Why MCF-7 and MCF-7/DOX cells display different 
preference to error-free and error-prone DSB repair strategies remains unknown, but 
triggering certain steps of preferred repair pathways may improve chemo- and 
radiotherapy response. Our data are in agreement with previous reports showing 
higher DNA repair potential of drug resistant cells (Shimm et al., 1988; Belli, 1989; 
Lehnert et al., 1990; Lehnert et al., 1994; Harris, 1985). 
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All types of DNA repair involve re-synthesis of DNA to replace the damaged 
strand. Therefore, DNA polymerases play key roles not only in DNA replication, but 
also in DNA repair processes (Hoeijmakers, 2001; Hoeijmakers, 2001). Specifically, 
high fidelity and processivity of polymerases is crucial for faithful DNA replication 
and preventing the accumulation of mutations. Indeed, efficient repair of DNA 
synthesis depends upon the proper functioning of DNA polymerases. Eukaryotic cells 
have 15 polymerases that belong to several families (Bebenek and Kunkel, 2004). 
Members of the B-family of polymerases include the major eukaryotic DNA 
polymerases α, δ, ε (Bebenek and Kunkel, 2004; Shcherbakova et al., 2003; Kunkel 
and Burgers, 2008). Polymerases δ and ε harbor exonuclease activity (Bebenek and 
Kunkel, 2004). They partake in replication and processing of Okazaki fragments 
during replication processes and are implicated in repair of damaged DNA. As 
components of recombination complexes, they are able to repair double-strand breaks 
and partake in HR and NHEJ.  
Some members of the X-family of polymerases, such as polymerase β, are 
required for base excision repair. Polymerase β is not as accurate as replicative DNA 
polymerases because it lacks proofreading capability. Polymerase β is a key player in 
base excision repair, a mechanism that takes care of damaged bases and single strand 
breaks (Bebenek and Kunkel, 2004; Shcherbakova et al., 2003; Matsuda et al., 2003). 
In addition to replicative polymerases there are a number of translesion DNA 
polymerases, such as polymerase ι, another member of X family of polymerases. 
These polymerases are involved in bypassing DNA lesions that otherwise impede 
replication polymerases (Kunkel et al., 2003).  
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Detailed analysis of DNA polymerases δ, ε, β and ι demonstrated higher 
activity, but lower fidelity of polymerases in MCF-7/DOX resistant cells in 
comparison to MCF-7 cells (Figure 2.7 and Figure 2.8). Low fidelity polymerases are 
thought to be an evolutionary solution allowing for replication past damaged DNA 
and avoiding apoptosis (Beard et al., 2002; Goodman and Tippin, 2000). The ability to 
catalyze error-prone DNA synthesis belongs to DNA polymerase iota which was 
highly expressed in doxorubicin-resistant cells and was not detected in parental MCF-
7 cells (Figure 2.7). 
We also found higher exonuclease/proofreading activity in MCF-7 cells as 
compared to MCF-7/DOX cells. In the current study, we analyzed only 4 cellular 
DNA polymerases, therefore future analysis of other polymerases may shed more 
light on the mechanisms of chemo- and radiation resistance. In sum, this study 
revealed that drug-resistant MCF-7/DOX cells developed more rapid DNA repair, 
seemingly sacrificing the specificity and efficiency of this process to gain higher 
survival potential. In the long run this may lead to an increased probability of 
accumulation of mutations and further to the development of even more pronounced 
resistance phenotype.  
Further detailed studies are needed to determine the cellular and molecular 
processes that are altered in resistant cells, which allow them to survive genotoxic 
treatments such as irradiation. This study may therefore provide a roadmap for the 
analysis of the roles of DNA repair, function, effectiveness and apoptosis in responses 
to radiation, chemotherapy and combinations of both treatment modalities. 
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Figure 2.0. Radiation induced apoptosis in MCF-7 cells studied by Annexin V-
FITC assay. M1 – average number of Annexin V positive cells. Diagrams below the 
M1 counts represent general cell distribution and viability. Viable cells – Annexin V 
and PI negative (lower left quadrants); cells in early apoptosis – Annexin V positive 
and PI negative (lower right quadrants); cells in late apoptosis or necrosis – Annexin 
V and PI positive (upper right quadrants); dead cells – (upper left quadrants). The 
numbers represent averages of three independent experiments. 
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Figure 2.1. Radiation induced apoptosis in MCF-7/DOX cells studied by Annexin 
V-FITC assay. M1 – average number of Annexin V positive cells. Diagrams below 
the M1 counts represent general cell distribution and viability. Viable cells – Annexin 
V and PI negative (lower left quadrants); cells in early apoptosis – Annexin V positive 
and PI negative (lower right quadrants); cells in late apoptosis or necrosis – Annexin 
V and PI positive (upper right quadrants); dead cells – (upper left quadrants). The 
numbers represent averages of three independent experiments. 
 
 
 
 
 
 52 
 
Figure 2.2. Radiation-induced H2AX phosphorylation in MCF-7 and MCF-
7/DOX cells. A – MCF-7 cells; B – MCF-7/DOX cells. Results are presented as 
average number of γH2AX foci per cell ± SE, n = 200. ** - significantly different 
from the respective control; p < 0.01; *** - significantly different from the respective 
control; p < 0.001; Student‘s t-test.  #  - significantly different between the 
corresponding dose and time points in two cell lines- MCF-7 and MCF-7/DOX, 
p<0.05, Student‘s t-test.  Magnification, × 100. Red – DAPI and Green – γH2AX. 
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Figure 2.3. Phospho-ATM levels in MCF-7 and MCF-7/DOX cells before and 
after radiation exposure. Magnification, 100. 
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Figure 2.4. Cellular localization of phospho-ATM in MCF-7 and MCF-7/DOX 
cells before and after radiation exposure. Magnification, × 100. Blue – DAPI, and 
Green – p-ATM. 
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Figure 2.5. RAD51 expression in MCF-7 and MCF-7/DOX cells before and after 
radiation exposure. Magnification, × 100. Blue – DAPI, and Green – RAD51. 
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Figure 2.6. KU70 expression in MCF-7 and MCF-7/DOX cells before and after 
radiation exposure. Magnification, × 100. Blue – DAPI, and Red – KU70. 
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Figure 2.7. DNA Polymerase fidelity in MCF-7 and MCF-7/DOX cells. CT-
control; IR-irradiated cells; K – Klenow enzyme, a positive control; Pr – primer only, 
4 pM. Cell extracts were loaded in double repeats. An arrow indicates the 15bp band. 
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Figure 2.8. Expression of DNA Polymerases delta, beta, epsilon and iota in MCF-
7 and MCF-7/DOX cells. Representative blots from 3 independent experiments are 
shown. PVDF membranes were stained with Coomassie Brilliant Blue G-250 to 
confirm an equal amount of loaded sample.  
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CHAPTER 3: MODULATION OF DNA METHYLATION LEVELS 
SENSITIZES DOXORUBICIN-RESISTANT BREAST 
ADENOCARCINOMA CELLS TO RADIATION-INDUCED 
APOPTOSIS 
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ABSTRACT 
Chemoresistant tumors often fail to respond to other cytotoxic treatments such 
as radiation therapy. The mechanisms of the chemo-and radiotherapy cross resistance 
are not fully understood and are also believed to be epigenetic in nature.   
Here we hypothesized that MCF-7 cells and their doxorubicin resistant variant 
MCF-7/DOX cells may exhibit different responses to ionizing radiation due to their 
dissimilar epigenetic status.  
Similarly to the previous studies, we found that MCF-7/DOX cells harbor 
much lower levels of global DNA methylation than MCF-7 cells. Furthermore, we 
found that MCF-7/DOX cells had lower background apoptosis levels and were less 
responsive to radiation than the MCF-7 cells. Decreased radiation responsiveness was 
correlated with the significant global DNA hypomethylation of MCF-7/DOX cells. 
Here we for the first time show that radiation resistance of MCF-7/DOX cells 
can be reversed by an epigenetic treatment – application of methyl-donor SAM.  
SAM-mediated reversal of DNA methylation led to elevated radiation sensitivity of 
MCF-7/DOX cells. Contrarily, application of SAM on the sensitive and higher 
methylated MCF-7cells resulted in the decrease of their radiation responsiveness. 
These data suggest that a fine balance of DNA methylation is needed to insure proper 
radiation and drug responsiveness.  
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INTRODUCTION 
Conventional cytotoxic drugs frequently fail as a treatment modality due to the 
development of drug resistance that blocks their activity (Stavrovskaya, 2000). 
Acquired drug resistance is a multi-factorial phenomenon, involving multiple genetic 
and, most importantly, epigenetic mechanisms (Fojo, 2007; Gottesman, 2002; 
Stavrovskaya, 2000). ‗Genetic‘ refers to heritable changes in DNA sequence, whereby 
the occurrence of random drug-induced mutational events leads to formation of drug-
resistant cells (Fojo, 2007; Iwasa et al., 2006). ‗Epigenetic‘ refers to information 
contained in chromatin rather than in the actual DNA sequence (Jaenisch and Bird, 
2003), and the induction of epigenetic changes results in resistance to cytotoxic drugs 
(Brown and Glasspool, 2007; Chekhun et al., 2006; Glasspool et al., 2006). Epigenetic 
changes are heritably stable alterations and include DNA methylation, histone 
modifications and small RNA-mediated silencing (Jaenisch and Bird, 2003). 
A number of studies have indicated substantial alterations of epigenetic profile 
of drug-resistant cancer cells, including changes in DNA methylation, histone 
modification patterns and microRNA expression (Baker and El-Osta, 2003; Brown 
and Glasspool, 2007; Chekhun et al., 2006; Duesberg et al., 2007;  Fojo, 2007; 
Glasspool et al., 2006; Kovalchuk et al., 2008). DNA methylation changes in drug 
resistant cells comprise hypermethylation of numerous genes involved in DNA repair, 
cell cycle control and apoptosis (Glasspool et al., 2006; Teodoridis et al., 2004). 
Besides the hypermethylation-related acquired drug resistance, the hypomethylated 
status of some genes might cause similar chemotherapeutic responses (Chekhun et al., 
2006; Chekhun et al., 2007). In addition to gene-specific changes, drug resistant cells 
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and tumors also exhibit global DNA hypomethylation (Chekhun et al., 2006; Chekhun 
et al., 2007). 
Chemoresistant tumors often fail to respond to other cytotoxic treatments such 
as radiation therapy. The mechanisms of chemo-and radiotherapy cross resistance are 
not fully understood and are believed to be epigenetic in nature.  
Amongst a variety of chemotherapy drugs, doxorubicin is an anthracycline drug 
traditionally used in curative-intent adjuvant and palliative treatment of breast cancer 
(Dean-Colomb and Esteva, 2008; Di Leo et al., 2002; Fornari et al., 1994; Frederick et 
al., 1990; T. Scandinavian Breast Group et al., 2006). While doxorubicin is one of the 
most active breast cancer treatment agents, many patients develop treatment resistance 
and experience cancer relapse (Dean-Colomb and Esteva, 2008). The data on radiation 
responses of doxorubicin-resistant breast tumors are contradictory and the exact 
nature and mechanisms of radiation responses of chemoresistant tumor cells remain 
obscure. The frequency of radiation resistance in doxorubicin-treated tumors also 
suggests an epigenetic nature to this phenomenon. Understanding the mechanisms of 
aberrant treatment responses is crucial for developing novel strategies for sensitizing 
tumors to cytotoxic regimens. 
The dynamic characteristics and reversible nature of epigenetic methylation 
patterns suggest that this epigenetic parameter may be an attractive therapeutic target 
for reversing treatment resistance. Most importantly, in contrast to genetic alterations, 
epigenetic changes can be modified pharmacologically. Currently, DNA methylation 
inhibitors are being tested as potential anticancer agents. Small molecules that allow 
reversal of aberrant hypermethylation, such as 5′-aza-2′-deoxycytidine, are now 
entering clinical trials (Christman 2002).  
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Additionally, approaches are also available to reverse the loss of DNA 
methylation. S-adenosylmethionine (SAM) was proven to inhibit demethylation in 
vitro (Detich et al., 2003). SAM is a universal methyl donor which causes 
hypermethylation. SAM acts either by activating DNA methyltransferases or by 
inhibiting demethylation (Detich et al., 2003).  
Here, we analyzed and compared the radiation response of MCF-7 breast 
adenocarcinoma cells and their doxorubicin resistant variant MCF-7/DOX cells. We 
noted that MCF-7/DOX cells were more resistant to radiation than sensitive cells. 
MCF-7/DOX cells also exhibited global DNA hypomethylation as compared to native 
MCF-7 cells. For the first time, we show that radiation resistance in MCF-7/DOX 
cells can be reversed by an epigenetic treatment – the application of methyl-donor 
SAM.  
 
MATERIALS AND METHODS 
Cell lines and cell culture conditions 
MCF-7 and MCF-7/DOX multidrug-resistant human breast adenocarcinoma cell 
lines were previously developed and described (Chekhun et al., 2007; Kovalchuk et 
al., 2008). Cells were grown and maintained in Dulbecco‘s Modified Eagle‘s Medium 
(DMEM /F-12) with 2.5 mM L-Glutamine, without HEPES and Phenol Red 
(HyClone, Logan, UT), supplemented with 10% heat-inactivated fetal bovine serum 
(HyClone, Logan, UT), in the presence of antibiotics 100 U/mL penicillin and 100 
µg/mL streptomycin (Sigma-Aldrich Chemical Co., St. Louis, MO) in 5% CO2 
atmosphere at 37 ºC. Cells were treated daily either with vehicle as control or 100 mM 
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S-(5‘-Adenosyl)-L-methionine chloride (Sigma-Aldrich Canada Ltd., Oakville, ON, 
Canada) by direct addition to the regular growth medium under sterile conditions for 6 
days. Cells were harvested for analysis by trypsinization (Chekhun et al., 2007; 
Kovalchuk et al., 2008). 
Irradiation conditions 
Cells were irradiated at the confluency of 60% in DMEM. A radiation dose of 5 
Gy (90 kV, 5 mA) was applied in order to induce cellular radiation responses. Un-
irradiated cells served as control. Cells were harvested 24 hours after irradiation. All 
cells were tested in triplicate. Experiments were independently reproduced twice. 
DNA methylation assay 
Total DNA was prepared from cell suspensions using the Qiagen DNAeasy Kit 
(Qiagen, Valencia, CA) according to manufacturer‘s protocol. A well established 
radiolabeled [3H] dCTP extension assay was employed to evaluate global DNA 
methylation levels (Pogribny et al., 1999). The assay measures the proportion of 
CCGG sites that lost methyl groups on both DNA strands. HpaII is a methylation-
sensitive restriction enzyme that cleaves CCGG sequences when internal cytosine 
residues are unmethylated on both strands. MspI is an isoschizomer of HpaII that is 
not sensitive to methylation and cleaves DNA regardless of methylation status. Both 
enzymes leave a 5‘-guanine overhang after DNA cleavage. This overhang can be used 
for the subsequent single nucleotide extension with labelled [3H] dCTP. The extent of 
[3H] dCTP incorporation opposite to guanine in HpaII-treated DNA is directly 
proportional to the number of unmethylated CpG sites, while in MspI-treated DNA it 
is proportional to the total number of CpGs. The ratio between two indicates the level 
of methylation.  
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Briefly, 0.5 µg of genomic DNA was digested with 10 U of either methylation-
sensitive HpaII or methylation-insensitive MspI enzymes (Fermentas Canada Inc., 
Burlington, ON, Canada) for 16-18 h at 37 ºC. A third DNA aliquot (0.5 µg) of 
undigested DNA served as background control. A single nucleotide extension reaction 
was performed in a 25 µL reaction mixture containing 0.5 µg DNA, 10 X PCR buffer, 
1 mM MgCl2, 0.5 U Taq DNA polymerase, and 0.1 µL [3H] dCTP (57.4 Ci/mmol) 
(GE Healthcare, Arlington Heights, US) and incubated at 56 ºC for 1 h. The samples 
were applied to Whatman DE-81 ion-exchange filters and washed three times with 0.5 
M sodium phosphate buffer (pH 7.0) at room temperature. The filters were dried and 
processed for counting using a scintillation counter (Beckman LS 5000CE; Fullerton, 
CA). The [3H] dCTP incorporation into DNA was expressed as mean disintegrations 
per minute (dpm) per µg of DNA after subtraction of background. The percentage of 
methylation was calculated according to the formula:  
% M = 1 – ((HpaII – Ct) / (MspI – Ct))*100 %   . 
Annexin V assay  
For apoptosis detection, Annexin V-FITC Apoptosis Detection Kit I (BD 
Biosciences, San Jose, CA) was used according to manufacturer‘s protocol. Cells 
were grown on 75 cm² cell culture flasks and irradiated as previously described. The 
analysis was performed 24 hours after radiation exposure. Cells were harvested, 
washed with PBS, resuspended in 1X binding buffer, stained with Annexin V and 
propidium iodide (PI) for 15 min at 25 ºC in the dark and analyzed by flow cytometry. 
Flow cytometry was performed at the Flow Cytometry Core Facility (University of 
Calgary, Calgary, AB). The results were represented as percentage of gated Annexin 
V positive cells. 
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Statistical analysis 
Statistical analysis was performed using MS Excel 2007 and JMP5 software 
packages. 
 
RESULTS 
Different levels of radiation-induced apoptosis and DNA methylation in MCF-7 
and MCF-7/DOX cells 
Radiation exposure is known to induce apoptotic cell death in irradiated cells 
(Camphausen and Lawrence, 2008). Apoptosis is characterized by various changes in 
the cellular plasma membrane, the main of which is the translocation of 
phosphatidylserine (PS) from the inner layer to the surface of the membrane. Annexin 
V possesses a high affinity to PS and therefore allows early detection of apoptotic 
changes (Vermes et al., 1995). Here, we used the Annexin V/PI assay to study the 
levels of radiation-induced apoptosis in MCF-7 and MCF-7/DOX cells. Interestingly, 
the background apoptosis rate was much lower in MCF-7/DOX cells as compared to 
MCF-7 cells, which could be a characteristic feature of multidrug resistant cells 
(Figure 3.0). Ionizing radiation (IR) is a potent inducer of DNA damage and 
apoptosis. Exposure of MCF-7 cells to 5 Gy of X-rays led to a significant induction of 
apoptosis, while MCF-7/DOX cells were resistant to radiation-induced apoptosis 
(Figure 3.0) 
We hypothesized that MCF-7 and MCF-7/DOX cells may be differentially 
sensitive to radiation due to their distinct epigenetic status, specifically – different 
global DNA methylation levels. To test this hypothesis, we first reconfirmed the status 
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of DNA methylation in MCF-7 and MCF-7/DOX cells. The cytosine extension assay 
revealed that MCF-7/DOX cells had significantly lower levels of methylated CCGG 
sites as compared to MCF-7 cells. Specifically, 73.3% of CCGGs were methylated in 
MCF-7 cells and 57.4% in MCF-7/DOX cells (p<0.05, Student t-test). Radiation 
exposure led to a slight (5.5%) increase of methylated CCGG sites in MCF-7 cells. No 
significant radiation-induced DNA methylation changes were seen in MCF-7/DOX 
cells (Figure 3.1 A) 
SAM treatment reverses DNA hypomethylation and causes radiosensitivity in 
MCF-7/DOX cells 
We hypothesized that the modification of DNA methylation status may result in 
the increased responsiveness of MCF-7/DOX cells to radiation. To test this prediction, 
we treated the MCF-7 and MCF-7/DOX cells with methyl donor SAM for 6 days. 
After treatment, the cells were exposed to radiation and DNA methylation and 
apoptosis levels were analyzed.  
Treatment of cells with methyl donor SAM led to a significant increase in the 
level of methylation observed in both MCF-7 and MCF-7/DOX cell lines (Figure 3.1 
B). Specifically, application of 100 mM SAM caused an increase in methylation level 
up to 70% in doxorubicin resistant cells (p < 0.05, Student t-test) which, therefore, 
became close to the level of methylation in untreated sensitive MCF-7 cells (Figure 
3.1 A). Methylation increased up to 90% in MCF-7 cells after adding SAM (Figure 
3.1 B). Importantly, upon SAM treatment the global methylation levels in both cell 
lines became more similar to each other. Ionizing radiation did not affect global DNA 
methylation in SAM-treated MCF-7 or MCF-7/DOX cells.  
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Next, we analyzed IR-induced apoptosis in SAM-treated MCF-7 and MCF-
7/DOX cells. SAM treatment alone did not cause apoptosis in either cell line due to 
the non-toxic nature of SAM (Figure 3.2 and Figure 3.3). Importantly, we found SAM 
treatment increased radiosensitivity of previously radioresistant MCF-7/DOX cells 
(Figure 3.3) supposedly by increasing their methylation status. At the same time, 
MCF-7 cells, surprisingly, lost their sensitivity to radiation treatment after SAM 
treatment (Figure 3.2). Indeed, after SAM treatment, the levels of apoptosis decreased 
back to their background level. Such a response in drug sensitive cells could be due to 
the methylation and subsequent inactivation of some unknown anti-apoptotic genes, 
however, this requires further investigation.  
 
DISCUSSION 
In the current study, we analyzed the role of epigenetic DNA methylation status 
in MCF-7 and MCF-7/DOX cells and correlated this data with the radiation 
responsiveness of these cell lines. We found that MCF-7/DOX cells exhibited global 
hypomethylation as compared to sensitive MCF-7 cells (Figure 3.1 A).Our data 
correlates with previous findings (Chekhun et al., 2006). Importantly, drug resistant 
MCF-7/DOX cells were also resistant to radiation exposure. We hypothesized that if 
global DNA hypomethylation is responsible for the acquired treatment resistance, then 
inhibition of demethylation should result in a reversion to the sensitive phenotype. 
Because the demethylating enzymes which cause DNA hypomethylation are yet 
unknown, there are no specific inhibitors of hypomethylation (Szyf et al., 2004). SAM 
is an important cellular molecule that serves as a universal donor of methyl groups for 
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various processes including DNA methylation. Depletion of SAM levels in the cells 
can therefore result in DNA hypomethylation. After partaking in DNA methylation 
reactions, SAM is turned into S-adenosyl-homocysteine (SAH). Indeed, several 
studies have shown that the ratio of SAM to SAH in the cell is related to changes in 
DNA methylation (Castro et al., 2005; Yi et al., 2000). Furthermore, SAH has an 
inhibitory effect on DNMT activity (Hoffman et al., 1979). Since doxorubicin 
acquired chemoresistance is associated with increased detoxification of free radicals 
by the glutathione system (Stavrovskaya, 2000), which uses SAM as methyl donor for 
glutathione-S-transferase, the resulting depletion of SAM could cause DNA 
hypomethylation. Therefore, SAM treatment was chosen as a method to counteract 
hypomethylation in MCF-7/DOX cells (Pakneshan et al., 2004; Shukeir et al., 2006).  
Previously, it has been observed that SAM treatment caused DNA methylation 
in tumours, with the methylation maintained for several weeks even after withdrawal 
of SAM (Shukeir et al., 2006). In our study, daily SAM treatment for 6 days caused a 
significant increase in DNA methylation levels of MCF-7 and MCF-7/DOX cells. 
SAM-mediated DNA methylation was correlated with an increase in radiation 
sensitivity of MCF-7/DOX cells. Contrarily, application of SAM to the sensitive 
MCF-7 cells, originally more methylated than MCF-7/DOX cells, resulted in a 
decrease in their radiation responsiveness. This data suggests that a fine balance of 
DNA methylation is needed to insure proper radiation and drug responsiveness.  
Overall, our study is the first to show a correlation between radiation 
responsiveness and global levels of DNA methylation in cells. Future studies are 
needed to identify in detail the loci that change methylation status upon SAM 
treatment in both cell types.  
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Although further investigations are required to understand the mechanisms of 
SAM action and hypermethylation consequences, our study suggests that inhibition of 
hypomethylation could be a novel epigenetic approach to clinical chemo- and 
radiation-resistance and ultimately increase patient survival. 
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Figure 3.0. Radiation-induced apoptosis in MCF-7 and MCF-7/DOX cells. The 
number of cells in early apoptosis was measured using Annexin V-FITC assay for 
control non-irradiated (CT) and irradiated with 5 Gy of X-rays cells (IR). The results 
are presented as mean values ± S.E.M., n=6. * - significantly different from the 
respective control, p<0.05; ** - significantly different from respective MCF-7 cells, 
p<0.05, Student‘s t-test. Black bars – MCF-7 cells, and Grey bars – MCF-7/DOX 
cells.  
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Figure 3.1 Global DNA methylation levels in MCF-7 and MCF-7/DOX cells. The 
levels of DNA methylation were mesured using the cytosine extension assay for 
control (CT), and irradiated with 5 Gy of X-rays cells (IR) (A), and for 100 mM SAM 
treated (SAM), and irradiated with 5 Gy of X-rays after SAM treatment cells 
(SAM+IR) (B). The results are presented as mean values ± S.E.M., n=4; * - 
significantly different from MCF-7, p<0.05. Black bars – MCF-7 cells, and Grey bars 
– MCF-7/DOX cells. 
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Figure 3.2 Radiation-induced apoptosis in MCF-7 cells after SAM treatment 
studied by Annexin V-FITC assay. M1 – average number of Annexin V positive 
cells. Diagrams below the M1 counts represent general cell distribution and viability. 
Viable cells – Annexin V and PI negative (lower left quadrants); cells in early 
apoptosis – Annexin V positive and PI negative (lower right quadrants); cells in late 
apoptosis or necrosis – Annexin V and PI positive (upper right quadrants); dead cells 
– (upper left quadrants). The numbers represent averages of three independent 
experiments. 
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Figure 3.3 Radiation-induced apoptosis in MCF-7/DOX cells after SAM 
treatment studied by Annexin V-FITC assay. M1 – average number of Annexin V 
positive cells. Diagrams below the M1 counts represent general cell distribution and 
viability. Viable cells – Annexin V and PI negative (lower left quadrants); cells in 
early apoptosis – Annexin V positive and PI negative (lower right quadrants); cells in 
late apoptosis or necrosis – Annexin V and PI positive (upper right quadrants); dead 
cells – (upper left quadrants). The numbers represent averages of three independent 
experiments. 
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GENERAL DISCUSSION AND CONCLUSIONS 
Breast cancer is the most common type of malignancy in women (Parkin, 
2001; Parkin et al., 2002) with the worldwide incidence continuing to rise (Ellsworth 
et al., 2004). 
Cytotoxic chemotherapy is extremely important for adjuvant treatment of 
breast cancer. Amongst a variety of cytotoxic drugs, doxorubicin is widely used in 
curative-intent adjuvant breast cancer therapies (Budišic et al., 1998; Verma et al., 
2008). Doxorubicin is an intercalator which interferes with topoisomerase function, 
blocks replication and leads to induction of apoptosis (Fortune et al., 2000).  
Even though cytotoxic chemotherapy is an effective treatment modality, a 
significant number of patients develop treatment resistance which leads to worsening 
of prognosis and relapse (Efferth et al., 2008; Frenkel and Caffrey, 2001; Lehnert, 
1996). The development of cancer cells resistant to chemotherapeutic agents is a 
major clinical obstacle in the successful treatment of breast cancer (Budišic et al., 
1998; Verma et al., 2008). Understanding mechanisms underlying the development of 
drug resistance and predisposition is critical in saving lives. 
Ionizing radiation is another important treatment modality which is often 
combined with chemotherapy for management of breast cancer (Liang et al., 2003). 
However, drug-resistant breast cancer cells may fail to respond to radiation therapy 
(Ozols, 1988). Mechanisms of cross-resistance are not well understood. 
A number of studies have indicated substantial alterations of epigenetic 
mechanisms in drug-resistant cancer cells, including changes in DNA methylation. 
DNA methylation is crucial for regulation of gene expression and chromatin state and 
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therefore – for normal development, cell proliferation, and proper maintenance of 
genome stability in an organism (Jaenisch and Bird, 2003). 
The current study is aimed to analyze and compare the radiation response of 
MCF-7 breast adenocarcinoma cells and their counterparts resistant to doxorubicin 
(MCF-7/DOX).   
We discovered that MCF-7/DOX cells were much more resistant to radiation 
than MCF-7 cells. We determined that this difference was due to differences in 
radiation-induced DNA damage, repair and apoptosis as well as differences in the 
epigenetic DNA methylation profile. We have discovered that modulation of the 
epigenetic DNA methylaition profle of beast adenocarcomoa cells can reverse the 
radiation response of cells.  
The major findings of this thesis are: 
1. MCF-7/DOX cells accumulate less DNA double-strand breaks following 
radiation treatment when compared to drug sensitive MCF-7 cells, and it is 
accompanied with higher but less precise DNA repair capacity. 
2. Acquired doxorubicin resistance is associated with global DNA 
hypomethylation in MCF-7/DOX. 
3. S-adenosyl-methionine (SAM) treatment causes reversal of methylation 
patterns and increases radiation-induced apoptosis in MCF-7/DOX. 
Summary of contributions that our findings have made to already existing 
knowledge: 
1. There has been discovered a cross-resistance between chemo- and 
radioresistance in breast cancer cells. 
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2. It has been proved that an increased DNA repair potential of drug-resistant 
tumor cells contributes to the development of radioresistance. 
3. It has been shown that radiosensitivity of doxorubicin-resistant cells can be 
reverted by increasing the DNA methylation status. 
Our findings are important for: 
1. choosing the right modality for breast cancer treatment; 
2. predicting the development of resistance to already existing treatment 
methods; 
3. the development of novel epigenetic therapy strategies. 
 
PROSPECT OF FUTURE RESEARCH: 
The findings presented in this thesis characterize only several molecular 
mechanisms of resistance of breast cancer cells to chemo- and radiation therapy. The 
cellular response to cytotoxic agents includes a variety of defensive pathways that 
require further in-depth investigation. Similarly, further study is required to evaluate 
prospects of reversal of drug sensitivity using epigenetic therapy. Our suggestions for 
future studies are: 
1. Further investigate the role of epigenetic changes in chemoresistance of breast 
cancer cells. Specifically, detailed analysis of hypomethylated DNA sequences 
should be performed to reveal what types of dysregulated genes are involved 
in the development of resistance to chemotherapy. This is especially important 
as it has recently been proven that alterations of DNA methylation in cancer 
cells occur in defined regions, suggesting that they are locus-specific and 
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cause non-random global DNA dysregulation (Mohn et al., 2008; Weber et al., 
2005; Weber et al., 2007; Wilson et al., 2006). 
2. The phenomenon of drug resistance was explained using only one out of a 
whole variety of therapeutic drugs as an example. There is a whole cohort of 
other anthracyclines and hormonal agents that might be explored in order to 
make a more precise conclusion about driving mechanisms of multi-drug 
resistance. Therefore, we assume it would be interesting to analyze and 
compare the radiation response of MCF-7 cells that exhibit resistance to 
cisplatin, tamoxifen and faslodex – some of the most common drugs used for 
breast cancer treatment. 
3. The potential for reverting drug-resistant phenotypes by modifying the 
epigenetic status also needs to be studied. In the current study, we have 
obtained only preliminary data that allow us to propose a possible role of SAM 
as an epigenetic therapy agent for reversal of treatment resistance. 
Mechanisms of SAM actions are not fully understood, and it is necessary to 
investigate whether all genes are equally targeted by SAM, and if yes, whether 
it causes changes in the level of expression of tumor suppressor genes. 
4. In this thesis, we studied responses of MCF-7 breast adenocarcinoma cells. 
They represent an ER-positive tumor phenotype with low invasive potential. 
Breast cancer has a wide variety of different molecular phenotypes. In the 
future, it would be necessary to analyze drug and radiation response of several 
other breast cancer cell lines. 
Molecular markers of drug resistance identified in this study can serve as a 
foundation for the translational approach. Emerging evidence indicates the 
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existence and importance of another epigenetic mechanism for regulating gene 
expression. This mechanism is mediated by short non-coding RNAs (Bartel, 
2004; Bushati and Cohen, 2007; Sevignani et al., 2006). MicroRNAs 
(miRNAs) are of special interest as they inhibit the translation of a variety of 
proteins. MicroRNAs have only recently been identified as potent novel 
regulators of gene expression and as a novel class of potential tumor 
classifiers. Even though they are now well-established as important 
contributors to tumor development and chemoresistance, their functions have 
yet to be defined. Notwithstanding, if we define the roles of miRNAs in the 
regulation of anthracycline resistance, this will constitute a major 
breakthrough in the field of novel biomarkers for cancer prognosis and 
prediction of treatment responses. Therefore, miRNAs hold much promise as 
cancer and breast cancer drug resistance modulators and biomarkers.  
Overall, this thesis may serve as a roadmap for future analysis of tumour resistance to 
radio- and chemotherapy and for the development of novel epigenetic strategies for 
reversal of breast cancer resistance to cytotoxic treatment regiments. 
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